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ABSTRACT 
Objective: The overall objective of this study was to evaluate the relationship between 
different diseases of the prostate gland (Benign Prostate Hyperplasia (BPH), Prostatitis, 
and Prostate Cancer) as well as levels of Prostate specific Antigen (PSA) with 
periodontal disease. 
Methods: A subset of data from the VA Dental Longitudinal Study was used for this 
study. The total sample size was 352 subjects with at least one PSA reading. Diagnoses 
of diseases of the prostate gland (BPH, Prostatitis, and Prostate Cancer) and PSA were 
used as the main outcome variables. Measurements of periodontal disease [average 
clinical attachment loss (CAL), average probing pocket depth (APD), and number of 
teeth with severe bone loss (NTBL)] were used as the main predictors. Statistical analysis 
	 vi 
included descriptive, bivariate, and multivariate testing. For the final multivariate 
analysis, Generalize Estimating Equations (GEE) controlling for potential confounders 
was used. 
Results: The study subjects were predominantly Caucasian males. At baseline the mean 
age was 71 years, and the mean PSA level was 2.5 ng/ml. The proportion of subjects with 
prostate diseases at baseline was 79.6% for BPH, 7.4% for prostatitis, and 8.8% for 
prostate cancer. Using GEE models and after controlling for potential confounders we 
found an association between CAL and BPH, as for every millimeter increase in CAL the 
odds of having BPH increased by 41%. We have also found that those with BPH and 
CAL above 2.7mm have higher PSA levels than those with either condition alone. We 
have not found any relationship between BPH and APD or NTBL. We have also not 
found any relationship between PSA, Prostatitis, and prostate cancer with any of the 
measurements of periodontal disease used in this study. 
Conclusion: This study showed an association between an increase in CAL and BPH. As 
well as showing that those with BPH and CAL above 2.7mm have higher PSA levels than 
those with either condition alone. These findings support that periodontal disease could 
affect the health of the prostate gland in an aging population, as well as the importance of 
oral health as an important and integral part of general health and well-being.  
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DISEASES OF THE PROSTATE GLAND, PROSTATE SPECIFIC ANTIGEN 
AND PERIODONTAL DISEASE 
 
INTRODUCTION: 
Oral health is an important and integral part of general health and well-being, it is 
believed that there is a connection between oral health and systemic disease (Oral Health 
in America: A Report of the Surgeon General, 2000). The periodontium is made from: 
gingival tissue, periodontal ligaments, cementum, and alveolar bone. Each component 
has its own structural characteristics that directly relates to its physiological function. 
These different components work together to support and hold teeth in places. However, 
the functionality of the periodontium and retention of teeth are highly dependent on the 
health and coordination between the different components (Bartold, 2006). Currently 
periodontal disease is recognized as an "eco-genetic" disease, in which all bacteria, 
genetic polymorphism, local and systemic environmental factors, medications, and 
nutritional agents may affect the periodontal structure and its function in health and 
disease (Bartold, 2006). 
The inflammatory process of the periodontium is known as periodontitis and is 
characterized by destruction of the periodontal ligaments and loss of clinical attachment 
due to loss of the supporting alveolar bone. There are many clinical signs of periodontitis 
that include; edema, erythema, gingival bleeding upon probing with or without 
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suppuration, and tooth mobility with loss of adjacent alveolar bone support, is the one 
distinct radiographic sign of periodontitis. As any other disease, periodontitis ranges in 
severity between mild, moderate, and severe and it could be localized to few teeth or 
generalized to the whole mouth (American Academy of periodontology (a), 2000; 
American Academy of periodontology (b), 2000).  
The differentiation between the severities of periodontitis is based on probing 
depth and attachment loss. Mild and moderate periodontitis have pocket depths > 5 
mm or and attachment loss > 4 mm.  On the other hand, severe periodontitis has pocket 
depths and attachment loss greater than 5 mm and 6 mm respectively (Eke and Genco, 
2007). 
Several studies have been conducted to find an association between periodontal 
disease and systemic diseases (Dietrich and Garcia, 2005; and Kuo et al., 2008). Studies 
have linked periodontal disease with several systemic diseases including but not limited 
to: cardiovascular disease, stroke, diabetes mellitus, adverse pregnancy outcomes, 
respiratory diseases, osteoporosis, obesity, malnutrition, rheumatoid arthritis, and cancer. 
Some of the proposed mechanisms for this association include the direct effect of 
periodontal disease pathogens and bacteria found in plaque and periodontal pockets of 
patients with poor oral health that can directly or through possible episodes of bacteremia 
affect other organs (Offenbacher, 1996).  Another mechanism is the host inflammatory 
response in which periodontal disease leads to triggering systemic pro-inflammatory 
cytokines and tissue destructive mediators such as IL-1, IL-2, TNF-α, and C-reactive 
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protein (CRP) that is not only a marker of inflammation, but plays a role in tissue 
destruction by enhancing phagocytosis by macrophages of foreign and damaged cells. 
(Offenbacher , 1996; Loos et al., 2000; Birkedal, 1993; Noack et al., 2001). 
A study by Joshi et al. in 2010,  evaluated the association between periodontal 
disease and prostate specific antigen (PSA). PSA is an inflammatory marker produced by 
the prostate gland (Diamandis, 1997), and is usually elevated in patients with 
inflammation (prostatitis) or malignancy of the prostate gland (≥ 4 ng/ml) (Nadler et al., 
1999). In their study of 35 patients, they found that patients with moderate/severe 
prostatitis with ≥ 2.7 mm clinical attachment loss have higher PSA levels compared to 
those with either condition (Joshi et al., 2010)     
Although as far as our search there are no other studies published in this area, the 
results of this study are interesting and open the door for future studies in this direction, 
they cannot be generalized based on the fact that this can only be considered as a pilot 
study on a very small sample size, they did not measure other markers of inflammation, 
and there was no consideration or controlling for potential confounders that may include 
(age, race, socioeconomic status, smoking, alcohol intake, systemic diseases, 
medications, and body mass index BMI). 
In order to evaluate the relationship between periodontal disease and PSA, a 
longitudinal study with a large sample size should be conducted, taking into 
consideration the effects of potential confounders including age, race, socioeconomic 
status, smoking, alcohol intake, systemic diseases, medications, and BMI. 
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The goal of this longitudinal analysis study is to evaluate the relationship between 
different diseases of the prostate gland (Benign Prostate Hyperplasia, Prostatitis, and 
Prostate Cancer) as well as levels of Prostate specific Antigen (PSA) with periodontal 
disease in the Veterans Administration Dental Longitudinal Study Cohort (DLS), 
controlling for potential confounders like age, socioeconomic status, smoking, alcohol 
intake, systemic diseases, Medications, and BMI. 
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BACKGROUND AND LITERATURE REVIEW: 	
Periodontal disease Overview, Epidemiology, and Risk Factors / Markers: 
Periodontitis is an inflammatory disease of the periodontium, characterized by 
destruction of the periodontal ligament and loss of clinical attachment due to loss of the 
supporting alveolar bone. There are many clinical signs of periodontitis and they include; 
edema, erythema, gingival bleeding upon probing with or without suppuration, and tooth 
mobility with loss of adjacent alveolar bone support, and eventually tooth loss. 
Periodontal destruction happens through the direct effect of toxins from periodontal 
disease pathogens and bacteria found in plaque and periodontal pockets of patients with 
poor oral health, this destruction is also mediated by the host inflammatory response in 
which periodontal disease leads to triggering systemic pro-inflammatory cytokines and 
tissue destructive mediators such as IL-1, IL-2, TNF-α, and C-reactive protein (CRP) that 
is not only a marker of inflammation, but plays a role in tissue destruction by enhancing 
phagocytosis by macrophages of foreign and damaged cells. (Offenbacher, 1996; Loos et 
al., 2000; Birkedal, 1993; Noack et al., 2001). 
There is no clear case definition of periodontal disease, and usually different 
definitions are found in epidemiological studies (Cobb et al., 2009). Periodontal disease 
is usually measured using one or a combination of, pocket depth, attachment loss, and 
radiographic alveolar bone level. Pocket depth is measured by a probe and is widely used, 
but lacks the ability to show the state and severity of the disease. Clinical attachment loss 
and alveolar bone loss are more accurate in measuring periodontal disease, as clinical 
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attachment loss is the distance between the cemento-enamel junction and the base of the 
periodontal pocket, and alveolar bone loss is the amount of bone loss measured from the 
cemento-enamel junction and the alveolar bone crest measured on a radiograph 
(American Academy of periodontology (c), 2005). 
In order to have a consensus definition of periodontal disease, a workgroup made 
up of clinical experts in periodontology, periodontal disease epidemiology, and statistics 
came together and defined moderate periodontitis as having two or more interproximal 
sites with > 4 mm clinical attachment loss, not on the same tooth, or two or more 
interproximal sites with > 5 mm probing depth, not on the same tooth. Sever periodontitis 
was defined as having two or more interproximal sites with ≥ 6 mm clinical attachment 
loss, not on the same tooth, and one or more interproximal site with ≥ 5 mm pocket depth 
(Eke and Genco, 2007). 
Periodontal disease is a highly prevalent disease, and it is important to take into 
account the study population and the case definition used in such studies. Information on 
the prevalence of periodontal disease come from wide national surveys like the National 
Institute of Dental and Craniofacial Research (NIDR) as well as the National Health and 
Nutritional Examination Survey (NHANES) conducted by the National Center for Health 
Statistics, Information from smaller surveys and studies are used as well. The importance 
of a case definition can show when viewing the prevalence of periodontal disease, if the 
case definition of at least one site with ≥ 4 mm clinical attachment loss is used for a 
population with age between 55 and 65 the prevalence of periodontal disease is 
approximately 50%, compared to less than 20% in the same population when the case 
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definition changes to ≥ 6 mm clinical attachment loss. The prevalence is around 30% in 
adults when using ≥ 4 mm pocket depth on at least three to four teeth as the case 
definition (American Academy of periodontology (c), 2005). 
Several risk factors / markers have been found to modify periodontal disease; 
these modifications can affect the disease at several stages (initiation, course, and 
progression). Knowing these risk factors / markers can help in a better understanding of 
the disease prevalence and distribution (Albandar, 2002). 
Several risk factors / markers have been identified in the literature, with different 
impact on periodontal disease; these include but are not limited to: Age, Gender, race / 
ethnicity, socioeconomic status, genetics, oral hygiene, bacterial infections, smoking, and 
obesity. 
- Age: Periodontal disease is usually considered to be a chronic disease and 
usually shows an increase with age (American Academy of periodontology (c), 2005; 
Albandar, 2002). Results from surveys done by NIDR, NHANES, and the national survey 
are in agreement with this finding (American Academy of periodontology (c), 2005). In 
these surveys periodontal disease is mostly measured using pocket depth and attachment 
loss; when pocket depth is used alone; results from lager surveys show some 
inconsistency, in NHANES III when pocket depth was used alone, there was a steady 
percentage of adults with pocket depth ≥ 4 mm, with a decrease in age group of 80 - 90 
years old. On the other hand, when periodontal disease is measured using clinical 
attachment loss, there is continues increase in the prevalence of periodontal disease by 
age. (Cobb et al., 2009; Albandar 2002).  
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Using clinical attachment loss and alveolar bone loss in combination with pocket 
depth show an increase in periodontal disease with age. Studies show that there is a 
constant increase in alveolar bone loss with age, with a decrease in older age best 
explained by advanced tooth loss over the age of 80 (Albandar, 1990; Albandar et al., 
1999). 
- Gender: in general studies show a higher prevalence of periodontal disease in 
males compared to females; this could be explained by the differences in behavioral, 
physiological, and hormonal differences between the genders. In general males are 
thought to have more negative attitude to oral health with less frequent visits to the 
dentist, poorer oral hygiene with higher plaque and calculus deposits, and being more 
likely to smoke (American Academy of periodontology (c), 2005; Albandar, 2002; 
Albandar et al., 1999). 
Data from NHANES I, showed that males had a higher scores on the Debris and 
Calculus index compared to females. In NHANES III, males had a higher prevalence of 
periodontal disease compared to females in all measurements of the disease, with deeper 
pockets and more clinical attachment loss, the only deviation was in the age group of 85 -
90, which could be explained by more tooth loss in males at this age group. It was also 
found that males had 21% more teeth with calculus compared to females (Albandar, 
2002; Albandar et al., 1999). 
- Race / Ethnicity and Socioeconomic Status: there is a wide diversity in the 
prevalence of many disease including periodontal disease among different race / ethnicity 
and socioeconomic status. Studies show that this diversity is most likely due to the 
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socioeconomic status across different race / ethnicities rather than it being solely 
attributed to race / ethnicity alone (American Academy of periodontology (c), 2005; 
Borrel and Papapanou, 2005).  
Results from NHANES I, show that African Americans have higher prevalence of 
periodontal disease compared to whites. This is also observed in data from NHANES III 
where again the prevalence of periodontal disease was higher in African Americans, 
followed by Mexican Americans and then Whites (Albandar, 2002). 
Another analysis of data from NHANES III, showed that race / ethnicity and 
socioeconomic status, level of education, and income where all associated with the 
prevalence of periodontal disease, where African Americans with less education and 
lower income had a higher prevalence of periodontal disease, compared to those with 
better education and higher income in the Mexican American and White racial group 
(Borrell and Crawford, 2008). There is a global agreement on the association between 
higher prevalence of periodontal disease and those of lower education and income 
(Petersen and Ogawa, 2005). 
Among the different race / ethnic groups African Americans have the highest 
prevalence of periodontal disease (measured by the worst scores of pocket depth, 
attachment loss, and furcation involvement) followed by Mexican Americans and Whites, 
regardless of age. Studies suggest that this could be attributed to the fact that African 
Americans have poorer oral hygiene and are more likely to underutilize dental care 
compared to the other groups. The level of education and income as an integral part of 
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socioeconomic status could highly influence attitudes towards oral health, availability of 
insurance, and access to health care (Cobb et al. , 2009; Albandar, 2002). 
- Genetics:  There are different presentations of the extent and severity of 
periodontal disease; there are no epidemiological studies that investigate the relationship 
between genetics and periodontal disease, with most of these studies being in the form of 
clinical and laboratory studies (Albandar, 2002; American Academy of periodontology 
(c), 2005).  
In the U.S population, 10 - 15% are found to have an aggressive and severe form 
of periodontal disease, with genetics being considered as a risk marker (American 
Academy of periodontology (d), 2005). 
Chronic periodontitis is thought to be a disease of complex genetic mutation, 
making it difficult to locate. Single genetic mutations have been identified with rare 
systemic diseases that are associated with severe periodontal disease, such as beta-2 
integrin chain gene and cathepsin C gene with Papillion-Lefevre syndrome, Chediak-
Higashi syndrome, and leukocyte adhesion deficiency type 1 (American Academy of 
periodontology (d), 2005). 
A study by Michalowicz et al. 2000, found that around 50% of the variance in 
periodontal disease could be related to genetics; in their study of 169 monozygotic and 
dizygotic twins, with clinical parameters of periodontal disease being more similar in 
monozygotic twins (Michalowicz et al., 2000). 
Studies show that genetics cannot be considered as a strong risk marker of 
periodontal disease solely, but more as a factor that interacts with other risk factors such 
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as oral hygiene, diet, and smoking in terms of regulating the immune response to these 
factors (American Academy of periodontology (d), 2005). 
- Oral Hygiene and Bacterial Infections: Gingivitis has been strongly related to 
poor oral hygiene, while periodontitis is related to the host response rather than poor oral 
hygiene alone. Studies have shown a strong relationship between gingivitis and poor oral 
hygiene, while this association is much weaker in the case of periodontitis, maintaining 
good oral hygiene can reverse the process of gingivitis, while that is not observed in 
periodontitis once it has been established (American Academy of periodontology (c), 
2005; Albandar et al., 1994; Albandar et al., 1995). A study on health professionals found 
no association between poor oral hygiene and periodontal disease (Merchant et al., 2002). 
This does not come with agreement with results from NHANES I, where a relationship 
between poor oral hygiene in the form of plaque and calculus deposition and periodontal 
disease was observed  (American Academy of periodontology (c), 2005; Albandar, 
2002). 
At least 600 bacterial species have been found in dental plaque, with some 
identified as causative pathogen for gingivitis (Ramseier, 2005). Bacteria can be 
considered as a risk factor for periodontal disease, where different species of bacteria 
have shown different effects on the pathogenesis of periodontal disease. There is a 
general agreement that in order for the initiation and progression of periodontal disease 
both dental plaque and bacteria should be present (Wolff et al., 1994). 
 The American Academy of periodontology identifies the following bacteria as a 
group that harbors sub-gingival plaque and is closely related to chronic periodontitis: 
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Actinomyces actinomycetemcomitans, Bacteroides forsythus, Porphyromonas gingivalis, 
Prevotella intermedia, Fusobacterium nucleatum, Comylobacter rectus, and Treponema 
denticola (American Academy of periodontology (c), 2005). 
Porphyromonas gingivalis, Tannerella forsythia, Peptostreptococcus micros, and 
Actinobacillus actinomycetemcomitans have been identified as significant bacterial 
pathogens by Van Winkelhoff et al. (Van Winkelhoff et al., 2002). Porphyromonas 
gingivalis is believed to be associated with more chronic periodontitis (Slots, 1999; 
Albandar, 2002), Grossi et al. showed that higher odds of chronic periodontitis are 
associated with Porphyromonas gingivalis and Bacteroides forsythus (Grossi et al., 
1994). On the other hand Actinobacillus actinomycetemcomitans have been associate 
with more rapid attachment loss in aggressive forms of periodontitis, a longitudinal study 
showed that Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis were 
associated with more sever forms of aggressive periodontitis in seropositive patients to 
Actinobacillus actinomycetemcomitans compared to seronegative (Albandar et al., 2001). 
- Smoking: Smoking and the use of different forms of tobacco is considered to be 
a modifiable socio-behavioral risk factor, they have been associated with several chronic 
diseases with high mortality rate like: cardiovascular and pulmonary disease. Around 
30% of all cancers and 90% of oropharyngeal cancers are attributed to smoking or other 
forms of tobacco use. Smoking and tobacco use is considered to be a major risk factor for 
periodontal destruction, early tooth loss, and oral cancer (Petersen and Ogawa, 2005; 
Petersen et al., 2005). 
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Findings from NHANES I, show that regardless of age and oral hygiene, there is a 
relationship between smoking and periodontal disease (American Academy of 
periodontology (c), 2005).  This was observed as well in NHANES III where smoking 
accounted for 50% of chronic periodontitis (Tomar and Asma, 2000). In a longitudinal 
study by Paulander et al. it was found that smoking was a strong risk factor for alveolar 
bone loss and periodontal disease (Paulander et al., 2004), another study showed that 
smokers have double the rate of periodontal disease progression compared to non-
smokers, they also showed that periodontal disease develops 3 - 4 times earlier in life in 
smokers compared to non-smokers (Schatzle et al., 2009). 
Krall et al. found that smokers have a higher risk of tooth loss compared to non-
smokers, this risk can decline by stopping smoking, but it may take 12 years after 
stopping smoking for the risk to come to a level similar to non-smokers (Krall et al., 
1997). Dietrich et al. found an association between tooth loss and smoking as well, their 
findings suggest that heavy smokers have a three-fold higher risk of tooth loss compared 
to non-smokers, the risk declines after smoking cessation, but may need more than 10 
years of cessation for the risk to come to a level similar to non-smokers (Dietrich et al., 
2007). Both studies indicate dose and time dependence between smoking and periodontal 
disease. 
Other forms of smoking like pipes and cigars have been associated with poorer 
periodontal parameters, high risk of tooth loss, and higher risk of alveolar bone loss, 
studies have shown that pipe and cigar smoking have similar adverse effects on the 
		 14	
periodontium as cigarettes do (Krall et al., 1997; Dietrich et al., 2007; Albandar et al., 
2000; Krall et al., 1999). 
Smoking has adverse effects on healing of periodontal therapies, smokers have 
inferior treatment prognosis when having non-surgical scaling and root planning for the 
treatment of chronic periodontitis compared to non-smokers, the same is true for surgical 
and regenerative periodontal therapies, where smokers have less favorable outcomes 
compared to non-smokers (Jin et al., 2000; Tonetti, 1998). 
 Different mechanisms of action of smoking on the periodontium have been 
proposed. The effect of chemicals in tobacco and tobacco substitutes, such as hydrogen 
cyanide, carbon monoxide, and nicotine, have been proposed as the cause of the harmful 
effects of smoking on the periodontium (Ramseier, 2005). Another mechanism is by 
reducing the vasculature of the periodontium, with subsequent decline in the host 
response to bacterial pathogens (American Academy of periodontology (c), 2005). Other 
studies suggest that smoking affects granulocyte function in the periodontium, as well as 
stimulating other inflammatory cells to release cytokines and protease enzymes, leading 
to more destruction in periodontal disease (Soder et al., 2002).  
- Obesity: Obesity is a growing public health problem worldwide; more than one 
third of the U.S population was obese in 2005 - 2006 (Ogden et al., 2007). Obesity has an 
impact on both general and oral health, and has been associated with poor quality of life. 
There are many systemic complications to obesity that include but are not limited to: 
hypertension, coronary heart disease, stroke, type 2 diabetes mellitus, joint arthritis, and 
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premature death. Obesity could also have potential impact on oral health and the 
periodontium (MMWR, 2009; Ritchie, 2007). 
Almost all cross-sectional studies conducted on different population worldwide 
come to the same conclusion when evaluating the relationship between obesity and 
periodontal disease. A study in Brazil found a significant association between periodontal 
disease and obese adults (Veccachia et al., 2005). A study on Japanese women aged 40-
79 found an association between obesity and deeper periodontal pockets (Siato et al., 
2005). In the French population a study found a significant relationship between 
attachment loss and obesity, with a 30% increased risk of attachment loss for every 
5kg/m2  increment in BMI (Bouchard et al., 2006). In an analysis of data from Health 
2000 in Finland, they found body weight to be associated with deeper periodontal pockets 
in the studied population (Ylostalo et al., 2008). According to an assessment of NHANES 
III data in the U.S a significant relationship between obesity and periodontal disease was 
observed (Alzahrani et al., 2003; Wood et al., 2003). 
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Periodontal disease and Systemic Conditions / Diseases: 
 Studies have linked periodontal disease with several systemic diseases including 
but not limited to: cardiovascular disease, stroke, diabetes mellitus, adverse pregnancy 
outcomes, respiratory diseases, osteoporosis, obesity, malnutrition, rheumatoid arthritis, 
and cancer. We will go over the relationship between periodontitis and cardiovascular 
disease as well as diabetes as examples of studies in this area. The proposed mechanisms 
of these relationships, serve as models by which similar inflammatory mechanisms affect 
other parts of the body.  
 - Cardiovascular disease: The term cardiovascular disease (CVD) can include a 
wide array of conditions affecting cardiac musculature and the connected vascular system 
supplying the entire body. According to the World Health Organization (WHO), 
significant increase in the mortality rate due to CVD has been documented over the last 2 
decades. The incidence of CVD-related death has increased from 14.4 million in 1990 to 
17.5 million in 2005 (Fuster et al. 2010). The WHO projections have shown that in 2015 
there will be approximately 20 million CVD deaths. Approximately, 80 % of the CVD-
related deaths occur in low to middle income countries (WHO, 2005).  These high CVD 
related mortality rates are not limited to the older population but are also involving 
younger age groups. The prevalence of CVD related deaths in the 35 to 64 year-old 
population is approximately 40% in South Africa, 35 % in India, and 28 % in Brazil. In 
contrast, the prevalence of CVD related mortality in the same group is only 12 % and 9% 
in the USA and Portugal, respectively (Leeder et al. 2004). 
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Ischemic heart disease (IHD) is the most common type of CVD. It is 
characterized by significant narrowing or blockage of the coronary arteries, or other 
major arteries, that subsequently leads to the onset of angina, myocardial infarction, or 
vital organ infarcts. IHD is the largest cause for global mortality with an average 
incidence of 7.6 million per year (Nabel, 2005). Cerebrovascular disease is defined by 
narrowing, blockage or hemorrhage in cerebrovascular system. It is known to be the 
second most common CVD with a yearly mortality rate of 5.7 million (Fuster et al. 
2010). 
Several risk factors are involved in the pathogenesis of CVD. Smoking and 
passive smoking are the most commonly associated risk factors, followed by chronic 
hypertension and hypercholesterolemia (Mirzaei et al., 2009; Shopland, 1995). A 
longitudinal study by Clarke et al., was able to demonstrate the association of these risk 
factors with a 10 to 15 year decrease in life expectancy (Clarke et al. 2009).  
Over the past two decades, several epidemiologic and laboratory investigations 
have explored the association between periodontitis and cardiovascular diseases. With the 
growing body of evidence, several reviews (Demmer and Desvarieux, 2006; Kebschull et 
al., 2010) and meta-analyses (Blaizot et al., 2009; Bahekar et al. 2007) have concluded 
that there might be association between the two conditions but the causal and effect 
relationship is still unrevealed. 
A meta-analysis by Blaizot et al concluded that - based on cohort studies- the risk 
of developing CVD can be significantly higher in people with periodontal disease 
compared to subject with good periodontal health (the pooled risk ratio was 1.34 95% CI 
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1.27 - 1.42 p<0.0001) (Blaizot et al., 2009). Another meta-analysis by Bahekar et al 
reported a low to moderate association between periodontal diseases and CVD with an 
OR ranging between 1.03 95% CI 1.01- 1.04 and 8.5 95% CI 1.1- 68.2 (Bahekar et al. 
2007). A case-control study by Geismar et al. showed a positive association between 
severe periodontitis and coronary heart disease in subjects below the age of 60, while no 
significant correlation was found among those who are 60 and above (OR 6,6 95% CI 
1.69 - 25.6) (Geismar et al. 2007). Similar findings were reported by Demmer and 
Desvarieux, in which the correlation between periodontitis and CVD was significant in 
patients below the age of 60 (Demmer and Desvarieux, 2006). 
Several investigations have been conducted to explain the link between 
periodontitis and cardiovascular disease with several proposed pathophysiologic 
mechanisms in an effort to explain this association. Bacteremia, immune modulation and 
lipid metabolism are among the most important proposed mechanisms (Belstrom et al., 
2012).  
It has been proposed that bacteremia is among the key initiators for the cascades 
correlating periodontitis to CVD (Kebschull et al., 2010; Kebschull et al., 2011). 
Bacteremia was found to be positively correlated to the inflammatory status of the 
periodontium because the circulation in the oral region is less protected against bacterial 
invasion compared to other parts of the alimentary tract (Iwai, 2009). Oral bacterial 
DNA, including A. actinomycetemcomitans and P. gingivalis, has been isolated from 
atherosclerotic plaques during cardiac bypass surgeries (Fiehn et al. 2005). However, it is 
arguable that the presence of bacterial DNA can results from accumulation of bacterial 
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fragments brought by the circulation to the area of the atherosclerotic plaque. Kozarov et 
al has successfully shown the presence of live Porphyromonas gingivalis and 
Actinobacillus actinomycetemcomitans in the atherosclerotic plaques in patients with 
periodontitis (Kozarov et al., 2005).  Other studies showed that the proportion of 
periodontal pathogens bacteremia increases with worsening periodontal condition, 
making it hard to determine whether the quantity or the strain of bacteria that is 
correlated to the atherosclerotic changes in patients with periodontitis (Forner et al., 
2006; Socransky et al., 1998).  
Immune modulation by periodontal pathogens has been also proposed to be one of the 
initiating mechanisms that correlate periodontitis to CVD. Some human studies have 
indicated that active periodontal infection can perpetuate atherosclerotic changes through 
activation of Toll-like receptors (TLR's) in endothelial cells (mostly TLR-2 and TLR-4) 
(Yumoto et al., 2005; Hajishengallis et al. 2009). Exposure of human aortic endothelial 
cells to bacteria, resembling those found in periodontitis, resulted in an enhanced 
expression of TLR-2 and TLR-4 in endothelial cells (Yumoto et al., 2005).  Animal 
studies have shown accelerated formation of atherosclerotic plaques after intravenous 
injection with P. gingivalis (Li et al. 2002). In addition, the severity of periodontitis, 
caused by bacterial injections, was positively proportional with the levels of IL-6 in the 
blood and the size of the atherosclerotic lesions (Lalla et al., 2003).  
Hyperlipidemia is a well-established risk factor for CVD. Few studies were able to 
establish an association between lipid metabolism and the presence of active periodontitis 
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(Holmstrup, 2007; Losche et al., 2000). It has been demonstrated that periodontitis can be 
correlated to 8%, 13% and 39% increase in the levels of blood cholesterol, low-density 
lipoproteins (LDL) and triglycerides, respectively. This can directly enhance the 
development of CVD by decreasing the anti-atherogenic potential of high-density 
lipoproteins (HDL) (Losche et al., 2000). Intriguingly, it was shown that this effect can 
be reversed after successful periodontal therapy (Pussinen et al., 2003). 
- Diabetes: Diabetes is a metabolic disease characterized by high levels of blood 
sugars (Hyperglycemia), it occurs due to an absolute or relative lack of insulin. There are 
three main categories of diabetes: type 1 diabetes, type 2 diabetes, and gestational 
diabetes (Casanova et al., 2014; NIH, 2008).  
Type 1 diabetes was called insulin-dependent diabetes mellitus or Juvenile-onset 
diabetes. In type 1 diabetes the body’s immune system destroys pancreatic beta cells, the 
only cells in the body that make the hormone insulin that regulates blood glucose.  
Although the disease can occur at any age, usually children and young adults are the most 
affected, in adults type 1 diabetes accounts for 5% to 10% of all diagnosed cases of 
diabetes. There is no known way to prevent type 1 diabetes, individuals that are affected 
will need insulin replacement for the rest of their life (Casanova et al., 2014; NIH, 2008). 
Type 2 diabetes was called non-insulin-dependent diabetes mellitus or adult-onset 
diabetes. Type 2 diabetes occurs as a result of a defect of insulin uptake, it begins with 
insulin resistance in which all cells do not use insulin properly, as the need for insulin 
rises, the pancreas gradually loses its ability to produce it. Type 2 diabetes accounts for 
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90% to 95% of all diagnosed cases of diabetes, it is usually associated with older age, 
obesity, family history of diabetes, history of gestational diabetes, impaired glucose 
metabolism, physical inactivity, and race/ethnicity. Management of type 2 diabetes 
includes oral hypoglycemic medications, diet modification, and physical activity 
(Casanova et al., 2014; NIH, 2008). 
Gestational diabetes is a form of glucose intolerance diagnosed during pregnancy, 
it is common among obese women and women with family history of diabetes. During 
pregnancy, gestational diabetes requires treatment to normalize maternal blood glucose 
levels to avoid complications to the infant. Immediately after pregnancy 5% to 10% of 
women with gestational diabetes are found to have type 2 diabetes. Women who have 
had gestational diabetes have 40% to 60% chance of developing diabetes in the next 5-10 
years (Casanova et al., 2014; NIH, 2008). 
There is a high prevalence of diabetes in the U.S, in 2007, the total number of 
people with diabetes was 23.6 million which represents 7.8% of the population. In those 
20 years of age and older 23.5 million or 10.7% of the population have diabetes, 12.0 
million were males representing 11.2% of all men aged 20 years or older and 11.5 million 
were females representing 10.2% of all women aged 20 years or older. For those aged 60 
years or older 12.2 million or 23.1% of all people in this age group have diabetes. Having 
uncontrolled diabetes for a long time may lead to many complications including, 
neuropathy, nephropathy, retinopathy, altered wound healing, vascular disease, oral 
infections, and periodontitis (NIH, 2008).  
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Diabetes is associated with an increase risk of periodontal disease, as it has been 
constantly reported in epidemiological studies. Most studies have focused on type 2 
diabetes although type 1 seems to have the same effect on the risk of periodontitis 
(Casanova et al., 2014). There is strong evidence that diabetes is a major risk factor for 
gingivitis and periodontitis. Those with diabetes have deeper pockets, and more 
attachment loss and gingival recession compared to healthy individuals (Mealey and 
Oates, 2006; American Academy of periodontology (e), 2000). This is also observed in 
children with type 1 diabetes as 10% of them have increase attachment and bone loss 
compared to healthy controls with comparable plaque scores (Cianciola et al., 1982).  
Studies have shown the importance of glycemic control, as those with poorly controlled 
diabetes have more advanced periodontal diseases compared to those with controlled 
glucose levels (Mealey and Oates, 2006; American Academy of periodontology (e), 
2000). As far as the bidirectional relationship between periodontitis and diabetes, more 
research is needed as there is no conclusive evidence in the literature to support this 
finding (Mealey and Oates, 2006; Garcia et al., 2001). From the body of literature 
investigating the relationship between diabetes and periodontal disease, it is clear that 
both types of diabetes are major risk factors for periodontal disease (Mealey and Oates, 
2006). 
The way diabetes and periodontal disease are linked could be explained by the 
fact that diabetes affects polymorphonuclear leukocytes (PMNs). Diabetes decreases the 
chemotaxis, adherence, and phagocytosis capability of PMNs, these lead to defects in the 
activity and function of PMNs leading to an impaired immune response to bacteria in 
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periodontal disease. In the same manner, diabetes affects fibroblasts in the periodontium, 
leading to an impairment in collagen homeostasis and turnover. This collagen breakdown 
is also attributed to collagenase enzymes and cytokines like IL-1, IL-2, and TNF-α 
released by neutrophils (American Academy of periodontology (e), 2000). 
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The Prostate Gland: An Overview: 
Anatomy: 
The prostate gland is shaped as an inverted cone in which the apex is pointing 
downward, the base is referring upward, and the midgland is sandwiched in between. In 
an antro-posterior view, the gland lies with its long axis parallel to the anterior rectal 
wall. It is bordered superiorly by the bladder (ventrally) and the seminal vesicles 
(dorsally), and inferiorly by the urogenital diaphragm (Jung and Westphalen, 2012).  
The prostate is separated from the rectum posteriorly by the Denovillier fascia that is 2-
3mm in thickness. It is bordered laterally by the obturator interni muscles superiorly, the 
levator ani muscles inferiorly, and the pubic symphysis and the Santorini plexus of veins 
anteriorly (Jung and Westphalen, 2012). 
The prostate gland is generally divided into two components: nonglandular and 
glandular (McNeal, 1980; Myers et al., 2010). The nonglandular part consists of the 
fibromuscular stroma that is anteriorly located to the urethra-and is a common site of 
cancers-and the proximal prostatic urethra extending from the central prostate base to the 
midgland (where the ejaculatory ducts enter at the verumontanum). The preprostatic 
sphincters-that is largely responsible for urinary continence-encases the urethra and 
periurethral glandular tissue, starting from the bladder neck to the verumontanum. The 
distal prostatic sphincter- that also plays a role in urinary continence-extends from the 
apex of the gland to the penile corpus spongiosum through the urogenital diaphragm 
(Coakley and Hricak, 2000). 
The glandular part of the prostate consists of the peripheral zone, central zone, 
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transition zone, and periurethral glandular tissue (McNeal, 1980; Myers et al., 2010). The 
peripheral zone encompasses approximately 70% of the total size of the prostate in young 
men (Jung and Westphalen, 2012). It surrounds the gland posterolaterally and extends 
anterolaterally toward the fibromuscular stroma. It is a common site for prostate cancer 
where 75% of the cases arise in this zone (Jung and Westphalen, 2012). 
In young males, the periurethral glandular tissue makes less than 1% of the 
prostate while the transition and central zones represent approximately 5% and 25% of 
the gland, respectively (Jung and Westphalen, 2012). Superior to the base of the prostate 
and posteroinferiorly to the bladder lays the seminal vesicles. These paired lobulated 
glands taper distally into a small duct to joins the vas deferens and make the ejaculatory 
duct. A thin layer of connective tissue called the “true capsule” encapsulates the gland 
and the pelvic fascia that is known as the “false capsule” surrounds this capsule. The 
veins are mainly located between the true and false capsules. 
Prostate arterial supply comes mainly from the prostatic branches of the inferior 
vesical artery along with small branches from the middle rectal and pudendal arteries. 
The lymphatic vessels drain directly into the internal iliac lymph nodes (Dixon JS, Chow 
PH and Gosling JA, 1999). 
The autonomic nervous system provides dual innervation to the prostate gland 
from both sympathetic (noradrenergic) and parasympathetic (cholinergic) nerves that are 
part of the prostatic nerve plexus. The noradrenergic nerves stimulate prostatic 
musculature and close the bladder neck during ejaculation of the seminal fluid into the 
urethra. Cholinergic nerves are responsible for the innervation of the capsular smooth 
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muscles along with the space surrounding blood vessels. They also provide secretory 
stimulation to the glandular epithelium. Both cholinergic and noradrenergic fibers 
innervate the prostate stroma (Dixon JS, Chow PH and Gosling JA, 1999). 
Physiology: 
The main function of the prostate gland, which is regulated by testosterone, is to 
secrete the fluid portion of the semen that constitutes 50-75% of the seminal fluid. This 
protein and minerals rich milky fluid is added to the spermatozoa, from the seminal 
vesicles, to maintain nourishment and facilitate motility of the sperms during their 
passage through the vaginal tract during fertilization, It also protects the sperms by 
having a low PH to neutralize the acidic vaginal environment. Moreover, the prostate 
plays an important role in urinary continence. The muscles of the prostate, which are 
under involuntary nervous system control, are wrapped around the urethra. These 
muscles contract to slow and stop the urinary flow (Drevet, 2006; Fraser and Osiguwa, 
2004; Ram and Wolfner, 2007; Veveris-Lowe et al., 2007). 
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Prostate Specific Antigen (PSA) 
PSA is a member of the human kallikrein gene family. It is a 240–amino acid 
protein encoded on chromosome number 19 (McCormack et al., 1995). This 33-kDa 
serine protease enzyme is synthesized in the epithelial cells of the prostate gland acini, 
secreted into the lumen of the gland, and then carried throughout the prostatic ducts to be 
mixed with the semen (Diamandis et al., 1996). The function of PSA has not been 
completely demonstrated, but it is known to play an important role in preventing the 
coagulation of the seminal fluid. It liquefies the major seminal gel proteins (fibronectin 
and seminogelin I and II) and consequently lyses the seminal coagulum that releases 
motile sperms required for fertilization (Borgono et al., 2004; Robert et al., 1997). 
Lower concentration of PSA is also found in the serum in both bound (most 
common) and unbound (less common) forms (McGee and Herr, 1988). The normal 
average serum level for PSA is 4.0 ng/mL or less. Elevated levels can be attributed to 
several factors including ejaculation, BPH, prostate inflammation/infection, and recent 
urologic instrumentation (Stamey et al., 1987). Although PSA is not a highly specific 
test, it can be helpful for prostate cancer screening in elderly and high-risk patients. It is 
also used to monitor the effectiveness of cancer therapy in those affected. 
 
Other sources of PSA 
Recently, several investigators have elected against the term prostate-specific 
antigen and described it as a misnomer terminology. This is based on the fact that this 
enzyme- although produced in large amounts by the prostate- is not specific to the 
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prostate gland. PSA has been detected in other body fluids and tissues (De Ungria et al., 
2008). Female ejaculate has PSA in an amount that is comparable that found in semen 
(Wimpissinger et al., 2007). The second highest concentrations of PSA in biological 
fluids, after semen and female ejaculate, are found in amniotic fluid and breast milk 
(Diamandis and Yu, 1997). Moreover, PSA has been detected at low concentrations in 
the salivary gland tissue, urethral glands, endometrium, and breast tissue. PSA has been 
also detected in the serum of female patients with breast, uterine, and lung cancer. Tissue 
biopsies of some metastatic tumors can be stained for the presence of PSA in order to 
determine the original source of the malignancy (Chuang et al., 2007). 
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Diseases of the prostate gland: 
Benign Prostate Hyperplasia: 
- Epidemiology: Benign prostate hyperplasia is a condition that is commonly 
diagnosed in aging male populations. There is a noticeable increase in the prevalence of 
the condition from 25% in men between 40 and 49 years of age to over 80% in men who 
are between the age of 70 and 79 (Berry et al., 1984; Sarma and Wei, 2012). 
Ethnicity plays a role in the incidence, symptoms severity, and likelihood of 
having surgery of BPH. White and Asian men are at higher risk of developing BPH 
compared to blacks (Platz et al., 2000). White men who are of southern European descent 
are at higher risk for developing severe symptoms and undergoing BPH surgery 
compared to men of Scandinavian heritage (Platz et al., 2000). Asian men have lower 
probability of undergoing surgery although the relative risk for symptoms severity is 
comparable to that of whites (Platz et al., 2000).  
- Signs and Symptoms: Some patients with anatomical and histological signs of 
BPH are asymptomatic. However, 50% of those who are 60 years old and above report 
lower urinary tract symptoms (Chute et al., 1993). These reported symptoms are 
diagnosed as bladder storage or obstructive voiding symptoms (Sarma and Wei, 2012). 
Storage symptoms can be described as urinary frequency, urgency, incontinence, 
nocturia, and bladder pain/dysuria. Obstructive voiding includes urinary hesitancy, delay 
in initiation, intermittency, involuntary interruption, straining to void, weak stream, and 
incomplete emptying sensation. 
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Clinical progression from lower urinary tract symptoms to BPH is defined as 
worsening lower urinary tract symptoms, urinary incontinence, acute urinary retention, 
renal insufficiency, or recurrent urinary tract infection. This occurs in approximately 14% 
of the men within a 5-year follow-up period (Crawford et al., 2006). Faster progression is 
observed in elderly patients, larger size of the prostate, severe lower urinary tract 
symptoms, higher levels of prostate-specific antigen (PSA), and lower rates of urinary 
flow (Crawford et al., 2006; McConnell et al., 2003). 
- Pathophysiology: The pathophysiology of BPH is still illusive. The 
bioavailability of testosterone and its metabolite, dihydrotestosterone is believed to play 
an important role in the development of the histologic features of the condition (Bartsch 
et al., 2000). In addition, high levels of dehydroepiandrosterone and estradiol (Neuhouser 
et al., 2004),  insulin-like growth factors (Rohrmann et al., 2007), and inflammatory 
markers (e.g., C-reactive protein) may contribute in the pathophysiologic process (St 
Sauver et al., 2006; St Sauver et al., 2008; St Sauver et al., 2009).  
Other risk factors- with poorly understood mechanisms- have been described in 
the literature including obesity (Giovannucci et al., 1994), diabetes (Sarma et al., 2012), 
high levels of alcohol consumption (Parsons and Im, 2009), and physical inactivity (Platz 
et al., 1998). 
The process of micturition (passing urine) requires relaxation of the bladder 
detrusor muscle. Contraction of the muscle is also necessary to prevent bladder outlet 
resistance. BPH, with anatomical enlargement, causes static bladder-outlet obstruction, 
which is the most commonly reported lower urinary tract symptoms. 
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Other pathophysiologic etiologies for bladder obstruction may include α-
adrenergic axis activity (Schwinn and Roehrborn, 2008), detrusor hyperactivity mediated 
by muscarinic receptors (Andersson, 2004; Milsom et al., 2001), and - nonmuscarinic 
receptor stimuli (e.g., phosphodiesterase-5) (Andersson, 2004). 
- Diagnosis: In order to diagnose BPH, a complete medical history must be 
obtained with focus on neurological and urological aspects. This includes the evaluation 
of fluid intake (especially caffeinated beverages) and medication usage (diuretics and 
antihistamines) that are known to weaken the contraction function of the bladder (Sarma 
and Wei, 2012). Clinical examination of the prostate gland is performed using digital 
rectal examination (DRE). Laboratory investigations are also obtained including PSA 
levels and urinalysis. The latter is of a great importance to rule out hematuria, which 
might be an indication for urolithiasis or cancer of the prostate, kidney, or bladder 
(Grossfeld et al., 2001). It is also an indication in the presence of urinary tract infections 
to treat them prior to initiation of any other therapies. The primary care physicians can 
manage patients with uncomplicated lower urinary tract symptoms. On the other hand, 
those with complicated cases, such as patients with hematuria, bladder or prostate cancer, 
elevated PSA, bladder stones, spinal cord injury, stroke or Parkinson disease, are best 
referred to urologist for comprehensive examination and better intervention (Sarma and 
Wei, 2012). 
A very important and useful tool to evaluate the severity of the lower urinary tract 
symptoms is the American Urological Association Symptom Index (AUASI). It is a 
validated, quantitative, and self-administered diagnostic tool in which 0 indicates no 
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symptoms and 35 represents the worst symptoms (Barry et al., 1992). This measure 
guides physicians to the best modality of treatment and helps evaluating the response to 
therapy in which a 3-point increase or decrease is considered clinically significant (Barry 
et al., 1995). 
- Management: In patients with AUASI score less than 8 (mild or no symptoms), 
watchful waiting along with annual re-evaluation is recommended (McVary et al., 2011). 
Patients with AUASI score that is equal to or more than 8 (moderate-to-severe 
symptoms), pharmacologic treatment should be discussed and-if possible-initiated 
(McVary et al., 2011). The main goals of therapy are to improve urinary symptoms and 
limit the progression of the disease. Four classes of medication have proven efficacy and 
are widely used in the treatment of BPH: antimuscarinic agents, α-adrenergic–receptor 
blockers, 5α-reductase inhibitors, and phosphodiesterase-5 inhibitors(Sarma and Wei, 
2012). These medications should be used for a sufficient period of time before deeming it 
ineffective and switching to another class. 
The implementation of herbal medicine, such as saw palmetto supplement, for the 
treatment of BPH has been increasing. Unfortunately, randomized controlled trials have 
failed to demonstrate efficacy of these supplements and their use has not been supported 
by the American Urological Association (Bent et al., 2006; MacDonald et al., 2012). 
If pharmacological therapy can’t be applied, due to medical contraindication or 
lack of response, surgical intervention is the approach of choice. Transurethral resection 
or microwave thermotherapy of the prostate is the treatments of choice. Recently, the use 
of laser and bipolar transurethral resection of the gland have shown promising results 
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with less adverse effects (e.g. erectile dysfunction) (Lukacs et al., 2012; Seckiner et al., 
2006). 
 
Prostatitis: 
- Epidemiology: Prostatitis is a common inflammatory condition that accounts for 
2 million outpatient visits per year in the United States. In regular primary care and 
urology practices, approximately 8% and 1% of the cases are diagnosed as prostatitis, 
respectively (Collins et al., 1998). The prevalence of prostatitis is 14.2%, with an 
increased risk in aged male population. The risk of prostatitis is 1.7 times higher for men 
aged 40–49 years, and 3.1 times higher for men aged 50–59 years compared to 20–39 
years old men (Mehik et al., 2000). The average annual cost of medical care for 
prostatitis is approximately  $4,000 per patient (Calhoun et al., 2004).  
- Classification: The National Institute of Health has developed a classification 
system for prostatitis syndrome that includes 4 categories as following: acute bacterial 
prostatitis, chronic bacterial prostatitis, chronic prostatitis/chronic pelvic pain syndrome 
(in the absence of urinary tract infection), and asymptomatic inflammatory prostatitis 
(Krieger et al., 1999). 
- Signs, Symptoms and Diagnosis: Approximately, 5% to 10% of patients with 
prostatitis symptoms are diagnosed as acute or chronic bacterial prostatitis (de la Rosette 
et al., 1993). It is diagnosed depending on the reported symptoms, clinical examination, 
and microbiologic results (culture of prostatic fluid).  
Acute prostatitis is a life-threatening bacterial infection. Its diagnosis is confirmed 
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by culture and sensitivity and the treatment is relatively straightforward using 
antimicrobial agents. Chronic bacterial prostatitis is more complicated and is frequently 
associated with recurrent urinary tract infections that should be confirm by culture 
(Weidner and Ludwig, 1994). Escherichia coli causes 75 to 80% of the cases while other 
gram-negative rods and enterococci are the etiology for the rest of the cases. Patients may 
be asymptomatic between episodes or have continuous mild pelvic pain. 
Chronic pelvic pain syndrome is the most common type of prostatitis where no 
evidence of urinary tract infection is detected (Schaeffer, 2006). It is associated with 
symptoms of obstruction and manifested as perinial, rectal, prostate, penal, testicular, 
and/or abdominal pain (Litwin et al., 1999). These symptoms remain unchanged or 
improve over time, but some patients might experience an increase in the severity of 
symptoms. Both chronic pelvic pain syndrome and chronic bacterial prostatitis have been 
associated with infertility and/or semen abnormalities(Engeler et al., 2003; Motrich et al., 
2005).  
Asymptomatic inflammatory prostatitis is characterized by evidence of prostate 
inflammation with lack of genitourinary tract symptoms. It is usually discovered 
incidentally during investigations for other conditions including infertility or elevated 
PSA levels (Schaeffer, 2006).  
- Treatment: 
Acute Prostatitis: The treatment of acute prostatitis is simple and depends on 
prescribing antimicrobial agents according to the results of the culture. 
Chronic Prostatitis: Prostate-penetrating oral antimicrobial agent such as 
		 35	
fluoroquinolone or trimethoprimsulfamethoxazole is the first line of therapy for chronic 
prostatitis. The usual duration of treatment is approximately 4 weeks with some 
variations depending on the severity of the case and the pharmacological agent used 
(Schaeffer and Darras, 1990; Weidner et al., 1991). Local injections of antimicrobial 
agents into the prostate gland is also one of the treatment approaches that has proven its 
efficacy (Hu et al., 2002). If antimicrobial agents fail to stop the recurrence of urinary 
tract infections, low-dose of suppressive therapy is added to the treatment regimen for 
microbial eradication (Schaeffer, 2006). 
Chronic pelvic pain syndrome: due to the multifactorial pathophysiology, the lack 
of standard diagnostic testing, and the methodological limitations of the conducted 
studies have made the treatment of chronic pelvic pain syndrome uncertain. Before 
treatment initiation, symptoms severity and their impact on the patient’s quality of life 
should be evaluated. The NIH has developed a self-administered, nine-item tool called 
the Chronic Prostatitis Symptom Index. It assesses in evaluating the patient's baseline 
status and response to treatment (scores range from 0 to 43 points, with higher scores 
indicating more severe symptoms, and four to six points reduction is considered to be 
significant) (Litwin et al., 1999). The commonly prescribed medication for the treatment 
of chronic pelvic pain syndrome includes, antimicrobial agents, alpha-blockers, and 5α-
Reductase Inhibitors. Other uncommonly used agents with limited trials are mepartricin 
(that decreases prostate estrogen levels) and quercetin (an antioxidant) and both have 
showed significant improvement compared to placebo (De Rose et al., 2004). 
Asymptomatic inflammatory prostatitis:  No treatment is required for this type of 
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prostatitis. Some practitioners prescribe a course of an antimicrobial and anti-
inflammatory agent. However, there is lack of supporting evidence (De Rose et al., 
2004). 
 
Prostate Cancer: 
- Epidemiology: Prostate cancer has the highest age-specific incidence of any 
cancer in male gender. In the United States, it is estimated that 1 in 6 males- with median 
age of 68- will be diagnosed with prostate cancer, and that it will be the cause of 
mortality in approximately 1 in 34 males (Jemal et al., 2007). Blacks are 40% at higher 
risk of developing the disease and the rate of mortality in this group is doubled compared 
to other ethnic groups (Jemal et al., 2007). Fortunately, mortality rate of prostate cancer 
has been steadily declining over the last two decade. Studies have shown that between the 
years of 1999 and 2003, the disease has bee decreasing by 4% each year (Jemal et al., 
2007). This decrease is attributable to the new advances in early detection methodologies, 
diagnostic modalities and treatment options (Walsh et al., 2007). 
- Pathophysiology: Clinical and laboratory investigations have proposed the 
involvement of ras and myc oncogenes in the pathophysiology of prostate carcinoma 
(Thompson et al., 1989). New tumor lines have been developed for laboratory researches 
by infecting fetal cloacal tissues in mice with the ras and myc oncogenes using viral 
vectors. Moreover, mutation of RBCA1, RBCA2, hereditary prostate cancer gene 1 
(HPC1), androgen receptors, and vitamin D receptors have also been implicated 
(Gallagher and Fleshner, 1998; Struewing et al., 1997). 
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- Risk factors: Family history of prostate cancer is the most significant risk factor. 
Patients with history of prostate cancer in one of the first-degree relatives have double the 
risk of developing the disease. Five and 11-fold increase in the risk of the disease is 
associated with the presence of two and three affected first-degree relatives, respectively 
(Carter et al., 1991).  
Diets with high animal fat content have been correlated to the increased risk of 
prostate cancer (Ganry, 2005; Leitzmann et al., 2004). On the other hand, other dietary 
agents have been shown to have a protective effect against prostate cancer such as, soy, 
zinc, selenium, and vitamin E (Shimizu et al., 1991). Dietary impact has been 
demonstrated on Japanese and Chinese immigrants to Western countries where the 
increased incidence of prostate cancer has been reported (Shimizu et al., 1991).  
- Diagnosis: In high risk and/or symptomatic patients, prostate cancer is usually 
suspected if an elevated PSA or abnormal DRE were detected. In such cases, transrectal 
ultrasound–guided biopsy is indicated for definitive diagnosis. 
- Signs and symptoms: Early stages of prostate cancer are usually asymptomatic. 
When symptoms develop, they resemble those of BPH such as: frequent urination, 
nocturia (urination at bedtime), hematouria (blood in urine), dysuria (pain in urination) 
and difficulty initiating and maintaining a steady urination stream. Only one third of 
prostate cancer patients report one or more of these symptoms at the time of diagnosis, 
while two thirds are asymptomatic (Miller et al., 2003). Prostate cancer is also associated 
with sexual dysfunction, including difficulty achieving erection and pain upon ejaculation 
(Miller et al., 2003). Advanced stages of the disease can cause additional symptoms 
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including urinary and fecal incontinence and bone pain (especially in the ribs, pelvis and 
vertebrae) (Miller et al., 2003). 
- Evaluation and screening:  
Prostate specific antigen: The utilization of PSA screening has dramatically 
increased in the number of cases diagnosed as prostate cancer over the last 2 decades 
(Polascik et al., 1999). In prostate cancer patients, the impact of PSA screening on 
survival rate is still an area of debate. The American Cancer Society recommends annual 
prostate cancer screening starting at the age of 50 in low-risk population and at the age of 
40 for African American males or those who have a family history of the disease. This 
screening should consists of DRE and serum PSA level (Catalona et al., 1994). 
The exact cutoff point for an abnormal PSA value is not yet established. A serum 
level of 2.5 ng/mL or less in men below the age of 60 and 4.0 ng/mL or less in men aged 
60 years old and above are considered within normal range (Zhu et al., 2005). 
  Transrectal ultrasound–guided prostate needle biopsy: Abnormal DRE or high 
levels of PSA indicates transrectal ultrasound–guided prostate needle biopsy. Clinical 
investigations have demonstrated that an increased number of biopsy samples has 
participated in improving cancer detection and decreasing the chance of false-negative 
results (Naughton et al., 2000). This procedure is performed in the office setting and is 
well tolerated by the patients. Some self-limiting side effects have been reported 
including; hematuria, hematospermia, and hematochezia. Other severe complications 
such as; urinary retention, severe bleeding, sepsis has been documented to only occur in 
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5% of the affected patients. 
  - Staging: The prognosis of prostate cancer cases is directly related to the clinical 
staging of the disease (Pound et al., 1997). The clinical staging system depends mainly on 
serum PSA level, DRE abnormality, histologic grading and radiographic findings. 
DRE is performed to estimate the extent of the tumor. Accurate prediction of the 
size and the extent of the tumor cannot be achieved using this test due to its low 
sensitivity and specificity (Cooner et al., 1990). Clinical investigations have illustrated 
the significant understaging of the disease using DRE as the only diagnostic method 
(Walsh and Jewett, 1980).  
PSA is among the most important markers in staging prostate cancer. The level of 
serum PSA has been found to be proportionally correlated to the severity and extent of 
the disease (Rainwater et al., 1990). It was found that approximately 80% of patients with 
PSA levels below 4 ng/m develop an organ-confined cancer (Catalona et al., 1997). 
Moreover, about 66% of prostate cancer patients, in whom the serum levels fall between 
4 and 10 ng/mL, have organ-confined tumor. Also, more than 50% of prostate cancer 
patients, with serum PSA levels above 10 ng/mL, have a spreading disease (Catalona et 
al., 1997). 
A highly validated and widely accepted pathological grading system for prostate 
cancer is the Gleason grading system (Gleason, 1966). This system starts with grade one 
up to grade 5 obtained for both the primary and the secondary areas of the gland 
depending on the severity of the prostatic adenocarcinoma and based on the microscopic 
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features of the biopsy. The grades are then added together to determine the Gleason 
score. Several well-designed clinical researches have validated this scoring system to 
predict the prognosis of prostate cancer patients. Gleason grade 7 and above indicates 
poor prognosis and an increased risk of biochemical failure after cancer therapy 
(D'Amico et al., 1995).  
Several imaging modalities including, CT scanning, bone scanning, and 
endorectal MR imaging have been implicated in staging prostate cancer cases. Bone 
scanning is the most sensitive radiographic modality to detect bony metastases (Terris et 
al., 1991). For patients with PSA levels below 10 ng/mL, the probability of detecting 
bone metastases on a bone scan is 0.1%.  
TNM staging system is the most reliable and commonly used clinical staging 
system for prostate cancer, in which T represents tumor size, N refers to lymph node 
involvement, and M indicates distant metastasis (Greene, 2002). 
- Treatment:  
Treatment of localized prostate cancer: Treatment modalities for localized 
prostate cancer include, cryosurgery, radical surgery, external beam radiation, 
brachytherapy, and watchful waiting with or without hormonal therapy. The treatment 
modality is selected depending on patient age and life expectancy, presence of other 
comorbid condition (such as other chronic or debilitating disease), ability to tolerate 
treatment complications, and patient preference. 
Watchful waiting: In patients with a life expectancy less than ten years, watchful 
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waiting is usually the best alternative approach to definitive treatment. This approach is 
considered for elderly patients with low-grade, slowly progressing disease that is unlikely 
to affect their life spam. No intervention is required unless progression of the disease 
takes place (Carter et al., 2002). 
Radical prostatectomy: For patients with localized prostate cancer and with a life 
expectancy exceeding ten years, prostatectomy is the treatment of choice. While perineal 
prostatectomy is still performed in some selected cases, radical prostatectomy remains the 
most commonly performed procedures. It is reserved for those with clinically localized 
disease (stage T1–T2). The procedure involves removal of the prostate gland along with 
the reanstamosis of the bladder to the proximal urethra. Pelvic lymph node dissection is 
considered if lymph node involvement is detected. Following radical prostatectomy, the 
5-year progression-free survival rate is approximately 80% regardless the clinical stage 
(Pound et al., 1997). This surgical procedure is consequently associated with several post 
operative complications including incontinence, impotence, and bladder neck contracture 
(Meraney et al., 2005). Recently, nerve-sparing procedure has dramatically decreased 
post-operative complications (Rabbani et al., 2000; Walsh and Donker, 1982). Moreover, 
minimally invasive procedures, such as laparoscopic and robotic prostatectomy, are 
widely performed nowadays. The benefits of these new approaches include, smaller 
incision, minimal intraoperative bleeding, faster recovery, and lower rates of post-
operative complications (El-Hakim et al., 2006; Stolzenburg et al., 2005; Trabulsi and 
Guillonneau, 2005). 
Brachytherapy: This approach involves the direct transperineal placement of 
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radioactive seeds into the prostate gland. Effectiveness has been achieved in lower-grade 
cancers cases (Gleason score <7, PSA <10 ng/mL, and stage T1–T2) in which the results 
were found to be comparable to both radical prostatectomy and external beam radiation 
(Woolsey et al., 2003). Post-operative complications include urinary retention, urethral 
stricture, impotence, rectal mucosal ulceration, and rectal bleeding (Kutikov et al., 2006). 
External beam radiation: External beam radiation is the treatment of choice for 
patients with advance stages of prostate cancer (Hashine et al., 2005; Morris et al., 2005). 
It is administered in doses of 70 Gy. Recently, CT-based treatment and three-dimensional 
conformational radiation have proven their efficacy in delivering radiation with less 
adverse effects such as; diarrhea, hematuria, impotence, skin reactions, and hemorrhagic 
cystitis (Mangar et al., 2005). 
Cryotherapy: Cryoprobes are inserted into the prostate gland by transperineal 
approach. Freezing and thawing of the probes causes cellular injury and apoptosis. 
Similar to brachytherapy, it is effective in low-grade cases (Kutikov et al., 2006). 
Treatment for advanced prostate cancer: 
Hormonal therapy: Hormonal ablation (suppressing circulating androgens) can 
effectively relieve symptoms and delay clinical progression in prostate cancer patients 
(Messing, 2003). This can be achieved via surgical (bilateral orchiectomy) or medical 
castration. Estrogens, leutenizing hormone–releasing hormone agonists, and direct 
antiandrogen blocking medications have been utilized (Messing, 2003). 
Chemotherapy: In the past, this approach was only used to treat refractory 
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prostate cancer with metastases and severe bone pain. During the last decade, docetaxel-
based therapy has shown significant efficacy and participated in increasing survival rates 
in hormone refractory metastatic prostate cancer patients (Petrylak, 2005). The promising 
results from the docetaxel trials have increased the interest in treating advanced prostate 
cancer with chemotherapeutic agents (Petrylak, 2005).  
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Prostate Specific Antigen (PSA), diseases of the prostate gland, and 
periodontal disease: 
 The literature is filled with publications studying the relationship between 
systemic disease and periodontitis. However, there is a lack of studies investigating the 
relationship between diseases of the prostate gland or it’s marker (PSA) and periodontal 
disease. 
 PSA: Joshi et al. in 2010, published a study that aimed to evaluate the association 
between PSA levels in patient with chronic prostatitis and periodontal disease. They 
studied 35 subjects with prostatitis confirmed with a prostate needle biopsy, the subjects 
were above 21 years of age, did not have dental prophylaxis in the last 3 months and had 
at least 12 teeth. The periodontal exam included: clinical attachment loss, probing depth, 
gingival recession, bleeding on probing, and gingival and plaque index. Subjects were 
then divided based on the prostate needle biopsy into two groups: 23 subjects with 
non/mild prostatitis, and 12 subjects with moderate/severe prostatitis. In the result 
section, there was no presentation of subjects age or demographics. They divided the 
subjects again based on the median clinical attachment loss to those with 2.7mm or more 
clinical attachment loss and those with less than 2.7mm clinical attachment loss, there 
was no significant association between clinical attachment loss and prostate 
inflammation, as well as no statistically significant difference between the two groups of 
clinical attachment loss in PSA levels. There was no statistical difference in the mean 
periodontal parameters and the two groups of prostate inflammation, as well as no 
correlation between the periodontal parameters and PSA. The only statistically significant 
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difference was observed when subjects were divided into four groups based on the 
presence or absence of prostatitis and the level of clinical attachment loss based on the 
2.7mm cutoff, they found that those with moderate/severe prostatitis and clinical 
attachment loss more than 2.7mm had statistically significant higher PSA levels 
compared to those with either condition alone. They proposed three mechanisms to 
explain the association between periodontitis and prostatitis resulting in an increase in 
PSA, these mechanism were based on the role of proinflammatory cytokines like IL1 and 
TNF-α in both diseases. The first possible mechanism could be that periodontitis could 
indirectly exaggerate pre-existing inflammation of the prostate gland through circulating 
cytokines. The second proposed mechanism is that the inflammatory response causes a 
disruption in the epithelium of the prostate gland leading to PSA leakage into the 
circulation. The third possibility is that the inflammatory response associated with 
prostate gland enlargements leads to an increase in the production of PSA both locally 
from the gland itself as well as a non-prostatic source of PSA like the periodontium. 
Although the results  are interesting it should be noted that there are many limitations to 
this study, mainly the small sample size and that the study was cross sectional, there was 
no control group and there was no controlling for potential confounders like age, race, 
and smoking. There was no recording of changes of PSA levels over time and the 
division of severity of prostatitis was based on a needle biopsy that may not show the 
whole state of the gland (Joshi et al., 2010). This study can only be considered as a pilot 
study, In order to evaluate the relationship between periodontal disease and PSA, a 
longitudinal study with a large sample size should be conducted, taking into 
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consideration the effects of potential confounders. 
 The same group that published the previous article had a recent publication, 
where they wanted to evaluate if nonsurgical periodontal treatment in patients with 
chronic periodontitis and high PSA, affected prostate symptoms and circulatory PSA and 
cytokines (IL-1β and CRP) levels. Using the same inclusion criteria as the previous study 
the total sample was 27 subjects, they measured the same periodontal parameters as well 
as IL-1β and CRP before and after periodontal treatment. Most of the subjects had 
none/mild prostatitis based on the biopsy (21 out of 27), 15 subjects had prostate 
malignancy and 6 scored higher than 7 on the Gleason grading system. At baseline IL-1β 
and CRP levels were low between the different groups and therefore was dropped from 
future analysis. Overall, there was no statistically significant decrease in PSA levels 
before and after periodontal treatment. However, subjects who started with PSA levels 
higher than 4 ng/ml at baseline, showed statistically significant decrease in PSA after 
treatment compared to those with lower PSA levels at baseline. Their conclusion was that 
periodontal treatment in patients with high PSA levels  (>4 ng/ml) in chronic prostatitis 
and periodontitis, significantly improved PSA levels as well as symptoms of prostatitis. 
There explanation is similar to the previous study as periodontal therapy decreases 
proinflammatory cytokines, decreasing the inflammatory effect on the prostate gland. 
They also suggested that since periodontitis and category 1 and 2 prostatitis have a gram-
negative bacterial etiology, periodontal therapy eliminates periodontal pathogens and 
hence reduces the prostate glands exposure to bacteria and their toxins (Alwithanani et 
al., 2015). It should be noted that the same limitation of the previous study apply to this 
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study including, small sample size and that the study was cross sectional, there was no 
control group and there was no controlling for potential confounders like age, race, and 
smoking. 
 BPH: Boland et al. in 2013, found an association between benign prostate 
hyperplasia BPH and periodontal disease using linked electronic medical and dental 
records. In this study electronic dental records of patients who underwent treatment for 
periodontal disease and those who did not have periodontal treatment but had dental 
maintenance visits based on Common Dental Terminology (CDT) codes, were linked 
with their medical records using International Classification of Diseases 9th Revision 
(ICD-9) codes, the total sample was 2475 subjects with 1235 cases and 1240 controls. 
Their main aim was to discover any association between medical conditions and 
periodontal disease with out a previous hypothesis. They found associations that have 
been previously reported in the literature between periodontal disease and pregnancy and 
child birth problems, hypertension, hyperlipidemia, hypercholesterolemia, and diabetes 
mellitus both type 1 and type 2. The association between periodontal disease and BPH 
however had not been reported in the literature. In their analysis they limited it to those 
under the age of 70 years in order to have comparable cases and controls, they found that 
after controlling for age, race, diabetes, hypertension, circulatory system conditions, 
obesity, lipid conditions, and alcohol and tobacco abuses, there was a statistically 
significant relationship between periodontal disease and BPH (OR = 1.5, 95% CI 1.05-
2.10, P = 0.026) (Boland et al., 2013). In their explanation of the association they cited 
articles that linked periodontitis and erectile dysfunction (Zadik et al. 2009, Keller et al. 
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2012) as well as BPH and erectile dysfunction (Mcvary 2005, Costabile and Steers, 2006) 
and by that suggesting the association between BPH and periodontal disease.  Another 
explanation was the mutual role that inflammation plays in both diseases (Amar et al. 
2003, Nickel 2008), as both diseases have been associated with an increase in 
transforming growth factor beta (TGF-β) production, an important growth factor involved 
in the immune response and wound healing (Skaleric et al. 1997, Untergasser et al. 2005). 
It should be noted that with such a data set many limitations should be taken into 
consideration, including missing data. In using billing codes, the controls could have 
some diseases that were not coded or the patients received treatment elsewhere, this is the 
same as for medical coding as grouping the codes makes it hard to distinguish between 
the severity of the disease.  
 Although not directly a disease of the prostate gland, erectile dysfunction ED has 
been linked to periodontal disease, most of the studies done to find such association have 
their limitations being mostly on small samples, or using electronic billing codes for 
larger samples, using patient self-reporting questionnaires, and the cross sectional nature 
of these studies. We will present briefly some of the studies published in this area, as the 
previous article suggested that the association between BPH and periodontal disease 
could be explained by the association of both diseases with ED. 
 Zadik et al. 2009 was the first to suggest an association between ED and 
periodontal disease in young men, in their study they used a Sexual Health and Inventory 
for Men Questionnaire to gather the information on ED from the study subjects (Zadik et 
al., 2009). Another study found that among those with vasculogenic ED, those with 
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severe ED had the highest prevalence of chronic periodontal disease, they have also 
reported a non-significant positive correlation between periodontal disease and 
vasculogenic ED (Sharma et al., 2011). Oguz et al. 2012, found that after controlling for 
age, BMI, education level, and annual income there was a highly significant association 
between ED and the severity of periodontal disease (OR = 3.29, 95% CI 1.36-9.55, P = < 
0.01). A study with a larger sample size using diagnoses codes was able to identify 
32,856 subjects diagnosed with ED and compared their periodontal health to 162,480 
controls. They found that after controlling for age, obesity, alcohol abuse, monthly 
income, geographic location, coronary heart disease, diabetes, hypertension, and 
hyperlipidemia patients with ED were more likely to have a previous diagnosis with 
chronic periodontitis compared to controls (OR = 3.35, 95% CI 3.25-3.45, P = < 0.001) 
(Keller et al. 2012). Eltas et al. 2012, showed that among those with moderate or severe 
ED with chronic periodontal disease, those who received periodontal treatment showed 
and improvement in ED in 3 months compared to those who did not receive periodontal 
treatment as measured by the International Index of Erectile Dysfunction (Eltas et al., 
2012). 
 Most of the articles explain the possible mechanism of the association between 
ED and periodontal disease to be through endothelial dysfunction. Endothelial 
dysfunction is a very important event in the pathophysiology of ED (Kaiser et al., 2004). 
Periodontitis may increase endothelial dysfunction by one of these mechanisms: First, an 
increase in reactive oxygen species is associated with chronic inflammation in endothelial 
dysfunction (Higashi et al., 2002; Cai et al. 2000). Damage to the antioxidant system 
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could happen as a result of an over production of reactive oxygen species, contributing to 
endothelial dysfunction in patients with periodontitis (Higashi et al., 2008). Second, there 
is an increase in inflammatory markers like IL1, IL 6 and TNF-α in periodontitis (Ali et 
al., 2011). It was also found that there is a high risk of endothelial dysfunction with 
increases in levels of inflammatory mediators like IL 6, IL8 and TNF-α (Valchopoulos et 
al., 2006; Giugliano et al. 2004; Eaton et al. 2007). Finally, endothelial function can be 
affected directly by periodontal pathogens or their products (Forner, 2006). 
 
 In order to evaluate the relationship between different diseases of the prostate 
gland (Benign Prostate Hyperplasia, Prostatitis, and Prostate Cancer) as well as levels of 
Prostate specific Antigen (PSA) with periodontal disease, a longitudinal study with a 
large sample size should be conducted, taking into consideration the effects of potential 
confounders including age, race, socioeconomic status, smoking, alcohol intake, systemic 
diseases, medications, and BMI. 
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Aim of this study: 
  The aim of this longitudinal analysis study is to evaluate the relationship between 
different diseases of the prostate gland (Benign Prostate Hyperplasia, Prostatitis, and 
Prostate Cancer) as well as levels of Prostate specific Antigen (PSA) with periodontal 
disease in the Veterans Administration Dental Longitudinal Study Cohort (DLS), 
controlling for potential confounders like age, race, socioeconomic status, smoking, 
alcohol intake, systemic diseases, Medications, and BMI. 
 
Importance of this study:  
 The study will attempt to find an association between PSA levels, the different 
prostate diseases (Benign Prostate Hyperplasia, Prostatitis, and Prostate Cancer), and 
periodontal disease. PSA is considered an inflammatory marker, produced by the prostate 
gland and is usually elevated in patients with inflammation (prostatitis) or malignancy of 
the prostate gland. We will try to find if indeed periodontal disease is associated with an 
increase in PSA, suggesting the possibility for it being a non-prostatic source of PSA and 
thereby having an effect on prostate health. 
 Finding such an association can support the role of periodontal disease in other 
systemic diseases and emphasize on the importance of oral health as an integral and 
important part of general health and well being.   
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Hypothesis: 
1. PSA: 
 We hypothesized that there is a significant association between PSA level and 
(various measures of) periodontal disease. This hypothesis will be tested by the 
following null hypotheses:  
Hο1-1: There is no significant association between PSA levels and Average 
clinical attachment loss controlling for age, BMI, level of education, smoking, alcohol 
abuse, use of NSAIDs, BPH, flossing, and number of teeth present.   
Hο1-2: There is no significant association between PSA levels and Average 
probing pocket depth controlling for age, BMI, level of education, smoking, alcohol 
abuse, use of NSAIDs, BPH, flossing, and number of teeth present.   
Hο1-3: There is no significant association between PSA levels and the number of 
teeth with severe bone loss controlling for age, BMI, level of education, smoking, alcohol 
abuse, use of NSAIDs, BPH, flossing, and number of teeth present.   
Hο1-4: There is no significant differences in PSA levels among those without 
BPH and have an average CAL < 2.7mm and those (without BPH  and have CAL ≥ 
2.7mm, with BPH and CAL < 2.7 mm, and with BPH and CAL ≥2.7mm)  controlling for 
age, BMI, level of education, smoking, alcohol abuse, use of NSAIDs, flossing, and 
number of teeth present.   
Hο1-5: There is no significant differences in PSA levels among those without 
Prostatitis and have an average CAL < 2.7mm and those (without Prostatitis  and have 
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CAL ≥ 2.7mm, with Prostatitis and CAL < 2.7 mm, and with Prostatitis and CAL 
≥2.7mm)  controlling for age, BMI, level of education, smoking, alcohol abuse, use of 
NSAIDs, flossing, and number of teeth present.   
Hο1-6: There is no significant differences in PSA levels among those without 
Prostate cancer and have an average CAL < 2.7mm and those (without Prostate cancer  
and have CAL ≥ 2.7mm, with Prostate cancer and CAL < 2.7 mm, and with Prostate 
cancer and CAL ≥2.7mm)  controlling for age, BMI, level of education, smoking, alcohol 
abuse, use of NSAIDs, flossing, and number of teeth present.   
2. High and Low PSA levels:  
We hypothesized that there is a significant difference between those with low PSA 
levels (< 4ng/ml) and those with high PSA levels (≥ 4ng/ml) in their (various 
measures of) periodontal disease. This hypothesis will be tested by the following null 
hypotheses:  
Hο2-1: There is no significant difference between those with low PSA levels (< 
4ng/ml) and those with high PSA levels (≥ 4ng/ml) in their Average clinical attachment 
loss controlling for age, BMI, level of education, smoking, alcohol abuse, use of 
NSAIDs, BPH, flossing, and number of teeth present.   
Hο2-2: There is no significant difference between those with low PSA levels (< 
4ng/ml) and those with high PSA levels (≥ 4ng/ml) in their Average probing pocket depth 
controlling for age, BMI, level of education, smoking, alcohol abuse, use of NSAIDs, 
BPH, flossing, and number of teeth present.   
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Hο2-3: There is no significant difference between those with low PSA levels (< 
4ng/ml) and those with high PSA levels (≥ 4ng/ml) in their number of teeth with Severe 
bone loss controlling for age, BMI, level of education, smoking, alcohol abuse, use of 
NSAIDs, BPH, flossing, and number of teeth present.  
3. BPH: 
We hypothesized that there is a significant difference between those without BPH and 
those with BPH in their (various measures of) periodontal disease. This hypothesis 
will be tested by the following null hypotheses:  
Hο3-1: There is no significant difference between those without BPH and those with 
BPH in their Average clinical attachment loss controlling for age, BMI, level of 
education, smoking, alcohol abuse, use of NSAIDs, PSA level, flossing, and number of 
teeth present.   
Hο3-2: There is no significant difference between those without BPH and those with 
BPH in their Average probing pocket depth controlling for age, BMI, level of education, 
smoking, alcohol abuse, use of NSAIDs, PSA level, flossing, and number of teeth 
present.   
Hο3-3: There is no significant difference between those without BPH and those with 
BPH in their number of teeth with severe bone loss controlling for age, BMI, level of 
education, smoking, alcohol abuse, use of NSAIDs, PSA level, flossing, and number of 
teeth present.   
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4. Prostatitis: 
We hypothesized that there is a significant difference between those without 
Prostatitis and those with Prostatitis in their (various measures of) periodontal 
disease. This hypothesis will be tested by the following null hypotheses:  
Hο4-1: There is no significant difference between those without Prostatitis and those 
with Prostatitis in their Average clinical attachment loss controlling for age, BMI, level 
of education, smoking, use of NSAIDs, PSA level, flossing, and number of teeth present.   
Hο4-2: There is no significant difference between those without Prostatitis and those 
with Prostatitis in their Average probing pocket depth controlling for age, BMI, level of 
education, smoking, use of NSAIDs, PSA level, flossing, and number of teeth present.   
Hο4-3: There is no significant difference between those without Prostatitis and those 
with Prostatitis in their number of teeth with severe bone loss s controlling for age, BMI, 
level of education, smoking, use of NSAIDs, PSA level, flossing, and number of teeth 
present.   
5. Prostate Cancer: 
We hypothesized that there is a significant difference between those without Prostate 
Cancer and those with Prostate Cancer in their (various measures of) periodontal 
disease. This hypothesis will be tested by the following null hypotheses:  
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Hο5-1: There is no significant difference between those without Prostate Cancer and 
those with Prostate Cancer in their Average clinical attachment loss controlling for age, 
BMI, level of education, smoking, use of NSAIDs, PSA level, flossing, and number of 
teeth present.   
Hο5-2: There is no significant difference between those without Prostate Cancer and 
those with Prostate Cancer in their Average probing pocket depth controlling for age, 
BMI, level of education, smoking, use of NSAIDs, PSA level, flossing, and number of 
teeth present.   
Hο5-3: There is no significant difference between those without Prostate Cancer and 
those with Prostate Cancer in their number of teeth with severe bone loss controlling for 
age, BMI, level of education, smoking, use of NSAIDs, PSA level, flossing, and number 
of teeth present.   
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MATERIAL AND METHODS: 
 
Data source and study population: 
Data from the VA Dental Longitudinal Study (DLS) was used in this study. DLS 
participants are a subset of a larger study known as the VA Normative Aging Study 
(NAS), which is an ongoing observational study of aging and oral health of healthy men. 
This cohort was made mainly of initially healthy veteran men, primarily Caucasian, who 
received their medical and dental care out of the VA medical system.  The dental data 
collection began in 1968, and information on chronic diseases and important covariates 
through December 31, 2010 was used.  
Data for the DLS was gathered in cycles, with an approximate of 3 years 
separating each cycle. In each cycle, medical history and physical examinations were 
performed as well as gathering lab work, demographic information, smoking status, 
alcohol use and other dietary information.  The dental examinations were done by 
calibrated dental examiners, who performed an extensive oral and dental examination that 
included: number of teeth, dental decay, dental restorations, periodontal status, dental 
prosthesis, and radiographic examination.  
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Human subject approval: 
All participants in the study provided a written informed consent at each examination. 
This study was approved by the Institution Review Boards (IRB) of both Boston 
University and the VA Boston Health System. 
 
 
Data management:  
 Data was received in 3 separate SAS data files: The first file contained basic 
medical information over all cycles. The second file contained information about 
systemic diseases and the year they wore diagnosed. The third file contained mainly 
dental exam data as well as some demographic data. As the dental exam cycle did not 
always correspond to the medical exam cycle, a fourth data set was included that contains 
the year of each dental exam and the closest physical exam cycle and year. Not all dental 
exams have a match, so we used a later exam if it was within 2 years. All the data sets 
were merged, and a final data set was created and outputted as a new SAS data file. The 
total number of subjects who started the study was 1231, with a total number of 
observations reaching 21871. The mean number of cycles was 7.7 with a standard 
deviation of 4.5. The minimal number of cycles was 1 and the maximum was 15 for 
disease diagnosis. 
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PSA data:  
 To identify the first cycle in which PSA was first recorded, each cycle was called 
in separately and a catch variable was created if there was a PSA reading. This procedure 
revealed that the first recording of PSA was done in cycle 7 for only 2 subjects. Table 1 
shows the number of subjects who had a PSA reading in the corresponding cycle. 
 A data set containing all observations with PSA reading was created, with any ID 
with more than one PSA reading will have multiple lines with the PSA reading for its 
corresponding cycle with all the medical and dental information. The data contains 584 
subjects with at least one PSA reading. As some subjects had missing dental variables at 
baseline or had no teeth, those subjects were excluded and the number of subjects went 
down to 352 subjects. Table 2 shows the number of subjects corresponding to the number 
of PSA readings. 
 
Table 1:  Number of subjects who had a PSA reading in the corresponding cycle 
Cycle number 7 8 9 10 11 12 13 14 15 
Number of subjects with PSA reading 2 91 293 413 419 318 155 25 5 
 
 
Table 2:  Number of subjects with the number of PSA readings 
Reading 1st 2nd 3rd 4th 5th 6th 
Number of subjects 352 297 241 191 70 1 
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Description of variables: 
A complete list of the variables is presented in Table 3. 
 
Outcome variables: 
 The outcome variables for this study were prostate disease variables (benign 
prostate hyperplasia (BPH), prostatitis and prostate cancer) and prostate specific antigen 
(PSA) recorded as a continuous variable as well as a categorical variable based on a 4 
ng/ml cutoff. 
 BPH, prostatitis and prostate cancer were recorded	as present or absent with the 
year of disease diagnosis, we used the diagnosis date with the medical cycle date to see if 
the subject had the disease at that cycle, this process gave binary variables with the 
disease ether present or absent.  
PSA was recorded as a continuous variable in ng/ml, a binary variable for PSA 
was created to have either a high PSA level (PSA ≥ 4 ng/ml) or a normal PSA level (PSA 
≤4 ng/ml).  
 
Predictor variables: 
 In order to measure periodontal disease several variables were used or created:   
Clinical attachment loss was gathered as a continuous variable from four sites per 
tooth, a variable that averages clinical attachment loss per subject was created. Then 
clinical attachment loss was categorized based on 2.7 mm cutoff point, this cutoff point 
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was adopted from the study by Joshi et al. (Joshi et al., 2010), creating a binary variable 
for clinical attachment loss ≥ 2.7 mm and clinical attachment loss < 2.7 mm.  
Probing pocket depth was gathered as a continuous variable from four sites per 
tooth, a variable that averages probing pocket depth per subject was created. Then 
probing pocket depth was categorized based on 2.7 mm cutoff point, creating a binary 
variable with probing pocket depth ≥ 2.7 mm and probing pocket depth < 2.7 mm.  
A variable that records the average maximum proximal pocket depth was created; 
this was done by finding the maximum pocket depth for each tooth and then calculating 
the average. A variable that records the average maximum clinical attachment loss was 
created; this was done by finding the maximum clinical attachment loss for each tooth 
and then calculating the average. Based on the literature severe periodontitis can be 
defined as having two or more interproximal sites with CAL ≥ 6 mm, not on the same 
tooth, and one or more interproximal sites with PD  ≥ 5 mm. according to the above 
definition 3 variables were created, the first was having 1 or more proximal site with 
probing pocket depth equal or more than 5mm not on the same tooth, the second was 
having 2 or more proximal site with clinical attachment loss equal or more than 6mm not 
on the same tooth, and finally a third variable that include the presence of both of the 
above conditions.   
Alveolar bone loss from CEJ to root apex was gathered from the mesial and distal 
surface of each tooth, this is a categorical variable of gradations of 20% loss recorded on 
a 5-point Schei ruler on x-rays. We created 3 new variables that give the number of teeth 
per subject with 1. No bone loss, 2. Mild-moderate bone loss, and 3. Severe bone loss.  
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Tooth mobility was gathered per tooth on a categorical scale, we created 3 new 
variables that give the number of teeth per subject with 1. None or normal mobility, 2. 
Greater than normal mobility ≤ 1mm, and 3. Severe mobility ≥ 1mm.  
Number of teeth present was recorded for each individual at each PSA reading. A 
continuous variable to calculate the number of teeth lost from baseline was created.  
Three new categorical variables were created to divide subjects based on prostate 
disease (benign prostate hyperplasia, prostatitis, and prostate cancer) and having high or 
low CAL based on the 2.7 mm cutoff. 
 
Covariate and potential confounders: 
 Age in years was recorded as a continuous variable. Subject’s level of education 
was recorded in three categories 1. High school or less, 2. Some college, or college 
graduate. In order to assess the subjects socioeconomic status the level of annual income 
was recorded as 1. “Unknown”, 2. “less than $9,999”, 3.  “$10,000-14,999”, 4. “$15,000-
19,999”, 5. “$20,000-24,999”, 6. “$25,000-29,999”, 7. “$30,000-34,999” 8. “$35,000 or 
more”. 
 Body Mass Index (BMI) was calculated using weight in kg divided by height in 
square meters. Use of any form of tobacco, consuming more than 2 alcoholic drinks per 
day, and the use of non-steroidal anti-inflammatory drugs (NSAIDS); were recorded as a 
binary variable 1. Yes, and 2. NO. 
For disease variables each disease is recorded as present or absent and the year of 
disease diagnosis, we used the diagnosis date with the medical cycle date to see if the 
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subject had the disease at that cycle, this process gave binary variables with the disease 
ether present or absent. The diseases recorded are: cerebrovascular disease, CHD, COPD, 
diabetes, MI, and cancers other than prostate cancer. 
Flossing frequency was recorded as a dichotomous variable as either “never” or “at least 
once per month”. Brushing once or more a day as well as having any gum treatment or 
any cleaning were recorded as a binary variable 1. Yes, and 2. NO. 
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Table 3: List of study variables: 
Description  Description 
Subject ID  Diagnosis of Diabetes (categorical) 
Consumes more than 2 alcohol drinks/day 
(categorical) 
 Clinical attachment loss ≥ 2.7 mm vs.  
Clinical attachment loss  < 2.7 mm 
(categorical) 
Age in years (continuous)  Diagnosis of MI (categorical) 
Level of education (categorical)  Diagnosis of Cancer other than prostate 
cancer (categorical) 
Use of NSAID medications (categorical)  Do you brush once or more/day (categorical) 
Use of tobacco (categorical)  Number of teeth present (continuous) 
Body Mass Index (continuous)  Ever use floss (categorical) 
PSA level ng/ml (continuous)  Any gum treatment in past year (categorical) 
Diagnosis of Benign prostate hyperplasia 
(categorical) 
 Any cleaning in past year (categorical) 
Diagnosis of Prostatitis (categorical)  Average clinical attachment loss in mm 
(continuous) 
Diagnosis of Prostate cancer (categorical)  Average probing pocket depth in mm 
(continuous) 
Diagnosis of Cerebrovascular disease 
(categorical) 
 Number of teeth with No bone loss 
(continuous) 
Diagnosis of Congestive heart disease 
(categorical) 
 Number of teeth with Mild-moderate bone 
loss (continuous) 
Diagnosis of COPD (categorical)  Number of teeth with Severe bone loss 
(continues) 
PSA ≥ 4ng/ml vs. PSA<4ng/ml (categorical)  Number of teeth with No or normal mobility 
(continues) 
Number of teeth lost from baseline 
(continuous) 
 Number of teeth with Greater than normal 
mobility ≤ 1mm (continuous 
Time of PSA reading   Number of teeth with Severe mobility ≥ 1mm 
(continuous) 
Prostate cancer with CAL level (categorical)  Probing pocket depth  ≥ 2.7 mm vs. Probing 
pocket depth  < 2.7 mm (categorical) 
BPH with CAL level (categorical)  level of annual income (categorical) 
Prostatitis with CAL level  (categorical)  Year of the exam 
Severe Periodontitis: having two or more interproximal sites with CAL ≥ 6 mm, not on the same 
tooth, and one or more interproximal sites with PD  ≥ 5 mm. (categorical) 
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Data analysis plan:  
 All statistical analysis was performed using SAS statistical software version 9.1, 
and 0.05 level of significance. 
For statistical analysis we used only subjects who had complete PSA readings as 
well as having at least one tooth at baseline (the first PSA reading). 
 Descriptive data for baseline (first PSA reading) included means and percentage 
for the measured variables for disease, PSA levels, smoking and alcohol intake habits, the 
measured periodontal disease indicators, percentages of subjects in relation to different 
variables and percentage of missing teeth and teeth affected. 
 Bivariate analysis of PSA levels and the different prostate diseases (Benign 
Prostate Hyperplasia, Prostatitis, and Prostate Cancer) with the different periodontal 
disease indicators and the other variables, using Person and Spearman correlation 
coefficients, t-tests, ANOVA and Chi-square statistics as appropriate. 
 Since the DLS is a longitudinal study, in which observations are correlated and 
present a repeated measure, Multivariate analysis using Generalized Estimating 
Equations (GEE) models was used to evaluate the association between PSA levels, and 
the different prostate diseases (Benign Prostate Hyperplasia, Prostatitis, and Prostate 
Cancer) with the different periodontal disease parameters, controlling for potential 
confounders such as age, socioeconomic status, smoking, alcohol intake, systemic 
diseases, medications, and BMI. 
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RESULTS: 
 
 The study’s total sample size was 352 subjects with at least one PSA reading, 
with a total of 1152 observations. The mean number of PSA readings was 3.27 with a 
standard deviation of 1.37.  The minimum number of PSA readings was 1 and the 
Maximum was 6 readings. 
 A detailed description of the results is presented in the following sections, all 
statistical tests were done at α= 0.05 level of significance. 
 
Sample description and Baseline characteristics: 
 In order to describe our sample, the following tables 4.1 and 4.2 represent the 
characteristics of the entire population at baseline (first PSA reading), it should be noted 
that there are some subjects with missing information. 
 All the study subjects were white males, their age ranged between 56 to 92 years 
with a mean age of 70.9±6.6 years. 40.4% of the subjects had some college education 
verses 34.4% who were college graduates, and 25.3% with a high school degree or less. 
Around 66% of the subjects had an income ranging between $10,000 – 25,000 a year, 
with 13.6% making less than $10,000 and 16.2% making an annual income of more than 
$25,000. More than 92% reported no use of any form of tobacco, and only 18.6% 
reported consuming more than 2 alcohol beverages a day. The mean BMI for the study 
group was 27.7±3.6. 
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 PSA ranged between 0-39 ng/ml with a mean of 2.5±3.3 ng/ml, only 17% were 
considered to have high PSA levels (≥4ng/ml). The majority of the subjects 79.6% had 
Benign Prostate Hyperplasia (BPH) which could be expected in an aging group. 
However, only 7.4% had Prostatitis and 8.8% had Prostate cancer. 
 Most of the study population 70.5% reported using Non-Steroidal Anti-
Inflammatory medications (NSAIDs) regularly. In general most of the subjects were 
healthy, where only 3.4% had Cerebrovascular Disease (CBVD), 17.6% had COPD, 
7.4% were diabetics, 15.6% reported having an MI, 17.6% had cancer other than prostate 
cancer, and around a quarter of the subjects 24.2% reported having a form of Coronary 
heart disease (CHD). 
 In general, the study population had fair oral health and good oral hygiene habits. 
Almost all subjects 99.7% reported brushing their teeth at least once per day, while 
65.2% reported flossing their teeth once or more every month. 76.4% had their teeth 
cleaned and only 5% reported having any form of periodontal treatment in the past year
 The mean number of teeth present in the mouth was 21.6± 6.7. On average 
subjects had a mean of 2.5±1.2mm periodontal clinical attachment loss with a minimum 
of 0.6mm and a maximum of 8mm, 37.7% of subjects had an average periodontal clinical 
attachment loss ≥2.7mm. The average periodontal probing pocket depth was 2.1±0.3mm, 
with only 5.2% having an average periodontal probing pocket depth ≥2.7mm. The 
percentage of subjects with severe periodontitis was 28.7% based on having two or more 
interproximal sites with CAL ≥ 6 mm, not on the same tooth, and one or more 
interproximal sites with PD  ≥ 5 mm. 
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 Other measurements include tooth bone level and tooth mobility. For tooth bone 
level, the men number of teeth with no bone loss was 3.6±4.9, for the number of teeth 
with mild-moderate bone loss the mean was 16.7±6.3 teeth, and for the number of teeth 
with sever bone loss the mean was 1.1±1.8 teeth. For tooth mobility, on average the 
majority of the teeth present had no or normal mobility as the mean number of teeth with 
no or normal mobility was 21±7.2 teeth, for the number of teeth with greater than normal 
mobility ≤1mm the mean number of teeth was 0.5±1.1 teeth, and for the number of teeth 
with severe mobility the mean was 0.1±0.4 teeth. 
 
Table 4.1: Descriptive statistics of baseline (Continuous variables)  
Variable N Mean SD Min Max 
Age (years) 352 70.9 6.6 56 92 
PSA (ng/ml) 352 2.5 3.3 0 39 
BMI 334 27.7 3.6 19.8 40.5 
No. of teeth 352 21.6 6.7 1 32 
Average clinical attachment loss (mm) 345 2.5 1.2 0.6 8 
Average probing pocket depth (mm) 345 2.1 0.3 1.2 3.6 
No. of teeth with No bone loss  304 3.6 4.9 0 24 
No. of teeth with Mild-moderate bone loss  304 16.7 6.3 0 30 
No. of teeth with Severe bone loss  304 1.1 1.8 0 11 
No. of teeth with No or normal mobility  348 21 7.2 1 32 
No. of teeth with Greater than normal mobility ≤ 
1mm  
348 0.5 1.1 0 7 
No. of teeth with Severe mobility ≥ 1mm  348 0.1 0.4 0 4 
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Table 4.2: Descriptive statistics of baseline (Categorical variables)  
Variable N Categories Frequency Proportions 
Education 352 
High school or less 89 25.28% 
Some college 142 40.43% 
College graduate 121 34.38% 
SES 352 
less than $9,999 48 13.64% 
$10,000-14,999 59 16.76% 
$15,000-19,999 98 27.48% 
$20,000-24,999 77 21.88% 
$25,000-29,999 41 11.65% 
$30,000-34,999 9 2.56% 
$35,000 or more 7 1.99% 
Unknown 13 3.69% 
Use of any form of tobacco 345 No 320 92.75% Yes 25 7.25% 
Consumes more than 2 
alcohol drinks/day 344 
No 280 81.4% 
Yes  64 18.6% 
PSA level 352 <4ng/ml 292 82.95% ≥ 4ng/ml 60 17.05% 
Use of NSAID medications 349 No  103 29.51% Yes 246 70.49% 
BPH 352 No 72 20.45% Yes 280 79.55% 
Prostatitis 352 No 326 92.61% Yes 26 7.39% 
Prostate cancer 352 No 321 91.19% Yes 31 8.81% 
BPH with CAL level 345 
Low CAL No Disease 51 14.78% 
Low CAL Disease 164 47.54% 
High CAL No Disease 20 5.80% 
High CAL Disease 110 31.88% 
Prostatitis with CAL level  345 
Low CAL No Disease 200 57.97% 
Low CAL Disease 15 4.35% 
High CAL No Disease 119 34.49% 
High CAL Disease 11 3.19% 
Prostate cancer with CAL 
level 345 
Low CAL No Disease 198 57.39% 
Low CAL Disease 17 4.93% 
High CAL No Disease 118 34.20% 
High CAL Disease 12 3.48% 
CBVD 352 No 340 96.59% Yes 12 3.41% 
CHD 352 No 267 75.85% Yes 85 24.15% 
 
		 70	
(Continued) Table 4.2: Descriptive statistics of baseline (Categorical variables)  
Variable N Categories Frequency Proportions 
COPD 352 No 290 82.39% Yes 62 17.61% 
Diabetes 352 No 326 92.61% Yes 26 7.39% 
MI 352 No 297 84.38% Yes 55 15.63% 
Cancer other than prostate 352 No 290 82.39% Yes 62 17.61% 
Do you brush once or 
more/day 346 
No 1 0.29% 
Yes 345 99.71% 
Flossing frequency  345 
never 120 34.78% 
once/month or more 225 65.22% 
Any gum treatment in past 
year 347 
No 330 95.1% 
Yes 17 4.9% 
Any cleaning in past year 347 No 82 23.63% Yes 265 76.37% 
Clinical attachment loss 345 < 2.7 mm 215 62.32% ≥ 2.7 mm 130 37.68% 
Probing pocket depth 345 < 2.7 mm 327 94.78% ≥ 2.7 mm 18 5.22% 
Severe Periodontitis  345 
No 246 71.3% 
Yes 99 28.7% 
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Bivariate Analysis: 
 In this section we will present the bivariate analysis of PSA levels and the 
different prostate diseases (Benign Prostate Hyperplasia, Prostatitis, and Prostate Cancer) 
with the different periodontal disease indicators and the important independent variables 
of interest accounting for repeated measure using Generalized Estimating Equations 
(GEE). 
It should be noted that initially we ran an analysis without accounting for the fact 
that observations are correlated and present a repeated measure (using Person and 
Spearman correlation coefficients, t-tests, ANOVA and Chi-square statistics as 
appropriate), which leads to an increase in the sample size and decrease in the standard of 
error, this was done in attempt to capture any possible relationships between the outcome 
variables and the other variables, especially those of periodontal disease parameters 
which are the independent variables of interest.  
 
1. PSA as a continuous variable: 
 In order to account for repeated measures, GEE was used for PSA and the most 
important variables as a crude analysis Table 5.  Age was significantly associated with 
PSA as each year increase increases PSA levels by 0.1 ng/ml p = 0.0001. Out of the three 
prostate diseases, only BPH showed significant association with PSA as every shift from 
not having BPH to having BPH increases PSA by 1.1 ng/ml p = 0.004. The association 
between prostatitis and prostate cancer with PSA was β = 1.9 and 1.1 respectively.  
However, they did not reach statistical significance. 
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 For the main periodontal disease predictors, including average clinical attachment 
loss, average probing pocket depth, and number of teeth with severe bone loss, no 
statistically significant relationship with PSA was noted. 
    For BPH with average clinical attachment loss, those with “CAL <2.7mm with 
BPH” and those “CAL ≥2.7mm with BPH” had statistically significant higher association 
with PSA compared to “CAL <2.7mm without BPH” β = 1.1 and 1.7 respectively. For 
prostatitis with average clinical attachment loss, those with “CAL <2.7mm with 
prostatitis” and those “CAL ≥2.7mm without prostatitis” had statistically significant 
higher association with PSA compared to “CAL <2.7mm without prostatitis” β = 1.2 and 
0.6 respectively. For prostate cancer with average clinical attachment loss, only those 
with “CAL ≥2.7mm without prostate cancer” had statistically significant higher 
association with PSA compared to “CAL <2.7mm without prostate cancer” β = 0.5. 
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Table 5: Bivariate analysis using GEE of PSA (continuous) with key variables 
accounting for repeated measure  
Variable N Levels Β estimate P-Value 
Age 352 -------------------- 0.09 0.0001 
BPH 352 Yes 1.06 0.004 No (Ref) (Ref) 
Prostatitis 352 Yes 1.85 0.12 No (Ref) (Ref) 
Prostate Cancer 352 Yes 1.13 0.27 No (Ref) (Ref) 
Average clinical attachment loss (mm) 345 -------------------- 0.04 0.71 
Average probing pocket depth (mm) 345 -------------------- -0.48 0.18 
No. of teeth with Severe bone loss 304 -------------------- 0.10 0.26 
BPH with CAL level 345 
High CAL Disease 1.71 <0.0001 
High CAL No Disease 0.09 0.77 
Low CAL Disease 1.07 <0.0001 
Low CAL  No Disease (Ref) (Ref) 
Prostatitis with CAL level 345 
High CAL Disease 1.3 0.14 
High CAL No Disease 0.62 0.048 
Low CAL Disease 1.18 0.037 
Low CAL  No Disease (Ref) (Ref) 
Prostate Cancer with CAL level 345 
High CAL Disease 1.62 0.27 
High CAL No Disease 0.45 0.03 
Low CAL Disease -0.15 0.90 
Low CAL  No Disease (Ref) (Ref) 
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2. PSA as a categorical variable: 
In order to account for repeated measures, GEE was used for PSA and the most 
important variables as a crude analysis Table 6. It was found that being a year older 
increased the odds of having a high PSA level by 6% (OR= 1.06, 95%CI 1.03-1.08). 
Having BPH or having Prostatitis increased the odds of having high PSA level (OR= 
3.72, 95%CI 2.1-6.6 and OR= 2.18, 95%CI 1.1-4.3) respectively. Having prostate cancer 
did not seem to affect having high or low PSA levels. 
For the main periodontal disease predictors average clinical attachment loss, 
average probing pocket depth, and number of teeth with severe bone loss, an increase in 
any of these parameters did not seem to affect having high or low PSA levels. 
 
 
Table 6: Bivariate analysis using GEE of PSA (categorical) with key variables 
accounting for repeated measure  
 
Variable N Levels OR 95% CI P-Value 
Age 352 ----------- 1.06 1.03 ,1.08 <0.0001 
BPH 352 Yes 3.72 2.1 , 6.6 <0.0001 No (Ref) (Ref) (Ref) 
Prostatitis 352 Yes 2.18 1.1 , 4.3 0.025 No (Ref) (Ref) (Ref) 
Prostate Cancer 352 Yes 0.72 0.29 , 1.8 0.47 No (Ref) (Ref) (Ref) 
Average clinical attachment loss (mm) 345 ----------- 1.0 0.84 , 1.19 0.96 
Average probing pocket depth (mm) 345 ----------- 0.78 0.46 , 1.34 0.37 
No. of teeth with Severe bone loss 304 ----------- 1.02 0.93 , 1.11 0.70 	
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3. Benign Prostate Hyperplasia (BPH): 
In order to account for repeated measures, GEE was used for BPH and the most 
important variables as a crude analysis Table 7. It was found that being a year older 
increased the odds of having BPH by 8% (OR= 1.08, 95%CI 1.05-1.11). While having a 
unit increase in PSA levels did not seem to increase the chances of having BPH, 
however, having high PSA levels ≥4ng/ml increases the odds of having BPH by 43% 
compared to those with low PSA levels <4ng/ml (OR= 1.43, 95%CI 1.1-1.88). Having 
prostatitis or prostate cancer did not seem to affect having BPH. 
For the main periodontal disease predictors average clinical attachment loss was 
significantly associated with BPH (OR= 1.5, 95%CI 1.17-1.89) where a shift to having 
average clinical attachment loss ≥ 2.7 mm increased the odds of BPH by 50%, average 
probing pocket depth as well was statistically significantly associated with BPH but in 
the reverse direction (OR= 0.6, 95%CI 0.37-0.94). Number of teeth with severe bone loss 
did not seem to affect BPH. 
 
Table 7: Bivariate analysis using GEE of BPH with key variables accounting for 
repeated measure  
Variable N Levels OR 95% CI P-Value 
Age 352 ---------- 1.08 1.05 , 1.11 <0.0001 
PSA 352 ---------- 1.02 0.98 , 1.05 0.28 
PSA cat. 352 ≥ 4ng/ml 1.43 1.1 , 1.88 0.008 <4ng/ml (Ref) (Ref) (Ref) 
Prostatitis 352 Yes 1.68 0.45 , 6.26 0.44 No (Ref) (Ref) (Ref) 
Prostate Cancer 352 Yes 1.31 0.67 , 2.57 0.43 No (Ref) (Ref) (Ref) 
Average clinical attachment loss (mm) 345 ---------- 1.49 1.17 , 1.89 0.001 
Average probing pocket depth (mm) 345 ---------- 0.59 0.37 , 0.94 0.03 
No. of teeth with Severe bone loss 304 ---------- 1.05 0.93 , 1.18 0.41 
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4. Prostatitis: 
In order to account for repeated measures, GEE was used for BPH and the most 
important variables as a crude analysis Table 8. None of the important variables showed a 
relationship with prostatitis. The variables used included Age, PSA, BPH, Prostate 
cancer, and average clinical attachment loss and average probing pocket depth. It should 
be noted that not finding any statistically significant relationships and not using the 
number of teeth with severe bone loss as a predictor, might be due to the fact that a small 
proportion of the study sample have prostatitis 7.4%, and by that making it hard to detect 
statistical significance or perform statistical testing for some variables.  
 
 
Table 8: Bivariate analysis using GEE of Prostatitis with key variables accounting 
for repeated measure  
Variable N Levels OR 95% CI P-Value 
Age 352 ---------- 1.01 0.99 , 1.03 0.24 
PSA 352 ---------- 1.0 0.97 , 1.02 0.83 
PSA cat. 352 ≥ 4ng/ml 1.17 0.95 , 1.44  <4ng/ml (Ref) (Ref) (Ref) 
BPH 352 Yes 1.16 0.98 , 1.38 0.08 No (Ref) (Ref) (Ref) 
Prostate Cancer 352 Yes 1.04 0.87 , 1.26 0.65 No (Ref) (Ref) (Ref) 
Average clinical attachment loss (mm) 345 ---------- 1.03 0.97 ,1.09 0.35 
Average probing pocket depth  (mm) 345 ---------- 0.91 0.80, 1.05 0.21 
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5. Prostate Cancer: 
In order to account for repeated measures, GEE was used for prostate cancer and 
the most important variables as a crude analysis Table 9. It was found that being a year 
older increased the odds of having prostate cancer by 8% (OR= 1.08, 95%CI 1.05-1.11). 
A one unit increase in PSA increased the odds of having prostate cancer by 27% (OR= 
1.27, 95%CI 1.13-1.42). However having high PSA levels ≥4ng/ml did not seem to affect 
the odds of having prostate cancer, neither did having BPH or having prostatitis. 
For the main periodontal disease predictors average probing pocket depth was 
statistically significantly associated with prostate cancer but in the reverse direction (OR= 
0.4, 95%CI 0.18-0.82). Average clinical attachment loss and the number of teeth with 
severe bone loss did not seem to affect prostate cancer. 
 
 
Table 9: Bivariate analysis using GEE of Prostate cancer with key variables 
accounting for repeated measure  
Variable N Levels OR 95% CI P-Value 
Age 352 ---------- 1.08 1.05 , 1.11 <0.0001 
PSA 352 ---------- 1.27 1.13 , 1.42 <0.0001 
PSA cat. 352 ≥ 4ng/ml 0.70 0.35 , 1.42 0.33 <4ng/ml (Ref) (Ref) (Ref) 
BPH 352 Yes 1.07 0,55 , 2.08 0.84 No (Ref) (Ref) (Ref) 
Prostatitis 352 Yes 1.34 0.54 , 3.34 0.53 No (Ref) (Ref) (Ref) 
Average clinical attachment loss (mm) 345 ---------- 1.22 0.99 , 1.49 0.054 
Average probing pocket depth (mm) 345 ---------- 0.40 0.18 , 0.82 0.01 
No. of teeth with Severe bone loss 304 ---------- 1.01 0.93 , 1.10 0.78 
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Multivariate Analysis: 
 
 In this section we will present the multivariate analysis to test the association 
between PSA and the different prostate diseases (Benign Prostate Hyperplasia, Prostatitis, 
and Prostate Cancer) as the outcome and periodontal disease, being: average clinical 
attachment loss, average probing pocket depth, and number of teeth with severe bone loss 
as the main predictors, controlling for potential confounders that include: Age, BMI, 
level of education, use of tobacco, consuming more than 2 alcoholic beverages a day, the 
use of NSAIDs, flossing frequency and the number of teeth present. Generalized 
Estimating Equations (GEE) models were used, to account for the repeated measure and 
the correlated nature of the data. Summary tables of all the models are presented at the 
end of this section Tables 15.1 and 15.2.  
 
PSA as a continuous variable: 
 In this section we will be presenting 6 models in which we tested for the 
relationship between PSA as a continuous variable as the outcome and average clinical 
attachment loss, average probing pocket depth, number of teeth with severe bone loss, 
BPH with clinical attachment loss (CAL) levels, prostatitis with CAL levels, and finally 
prostate cancer with CAL levels as the main predictors, controlling for potential 
confounders that include: Age, BMI, level of education, use of tobacco, consuming more 
than 2 alcoholic beverages a day, the use of NSAIDs, flossing frequency and the number 
of teeth present. 
		 79	
1. PSA as a continuous variable and average clinical attachment loss: 
 The GEE model for PSA and average clinical attachment loss controlling for 
potential confounders is presented in Table 10.1. 
 After controlling for age, BPH, BMI, education level, tobacco use, consuming 
more than 2 alcohol beverages a day, the use of NSAIDs, flossing frequency, and the 
number of teeth present,  no statistically significant association was observed between 
PSA and average clinical attachment loss (β= -0.005, p=0.97). 
 However, Age and BPH seem to be major confounders, as every ear increase in 
age increases PSA by 0.06 ng/ml (β=0.06 p=0.003), and every switch from not having 
BPH to having BPH increases PSA by 1.1 ng/ml   (β=1.1 p=<0.0001). 
 There was no statistically significant association between PSA and BMI, 
education level, tobacco use, consuming more than 2 alcohol beverages a day, the use of 
NSAIDs, flossing frequency, and the number of teeth present. All the relationships were 
in a positive direction except for BMI and the use of tobacco: as for every unit increase in 
BMI and starting to use tobacco, PSA decreased by 0.07 and 0.14 ng/ml respectively 
Table10.1. 
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Table 10.1: Final GEE multivariate model to test the association between average 
clinical attachment loss and PSA as a continuous variable, controlling for potential 
confounders (N=352). 
 
Variable Levels Β estimate P-Value 
Intercept ----------------- -2.38 0.29 
Average clinical attachment loss 
(mm) 
----------------- -0.005 0.97 
Age ----------------- 0.063 0.003 
BMI ----------------- -0.07 0.097 
Education 
College graduate 0.48 0.098 
Some college 0.72 0.062 
High school or less (Ref) (Ref) 
Use of any form of tobacco Yes -0.14 0.75 No (Ref) (Ref) 
Consumes more than 2 alcohol 
drinks/day 
Yes 0.18 0.56 
No (Ref) (Ref) 
Use of NSAID medications Yes 0.34 0.17 No (Ref) (Ref) 
Flossing frequency Never 0.42 0.29 Once / month or more (Ref) (Ref) 
No. of teeth ----------------- 0.02 0.32 
BPH Yes 1.09 <0.0001 No (Ref) (Ref) 	
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2. PSA as a continuous variable and average probing pocket depth: 
 The GEE model for PSA and average probing pocket depth controlling for 
potential confounders is presented in Table 10.2. 
 After controlling for age, BPH, BMI, education level, tobacco use, consuming 
more than 2 alcohol beverages a day, the use of NSAIDs, flossing frequency, and the 
number of teeth present, no statistically significant association was observed between 
PSA and average probing pocket depth (β= 0.25, p=0.41). 
 However, Age and BPH seem to be major confounders, as every year increase in 
age increases PSA by 0.06 ng/ml (β=0.06 p=0.002), and every switch from not having 
BPH to having BPH increases PSA by 1.07 ng/ml   (β=1.07 p=<0.0001). 
 There was no statistically significant association between PSA and BMI, 
education level, tobacco use, consuming more than 2 alcohol beverages a day, the use of 
NSAIDs, flossing frequency, and the number of teeth present. All the relationships were 
in a positive direction except for BMI and the use of tobacco: as for every unit increase in 
BMI and starting to use tobacco, PSA decreased by 0.07 and 0.21 ng/ml respectively 
Table10.2. 
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Table 10.2: Final GEE multivariate model to test the association between average 
probing pocket depth and PSA as a continuous variable, controlling for potential 
confounders (N=352). 
 
Variable Levels Β estimate P-Value 
Intercept ----------------- -2.92 0.19 
Average probing pocket depth (mm) ----------------- 0.25 0.41 
Age ----------------- 0.064 0.002 
BMI ----------------- -0.07 0.09 
Education 
College graduate 0.47 0.11 
Some college 0.73 0.06 
High school or less (Ref) (Ref) 
Use of any form of tobacco Yes -0.21 0.64 No (Ref) (Ref) 
Consumes more than 2 alcohol 
drinks/day 
Yes 0.19 0.55 
No (Ref) (Ref) 
Use of NSAID medications Yes 0.35 0.16 No (Ref) (Ref) 
Flossing frequency Never 0.41 0.31 Once / month or more (Ref) (Ref) 
No. of teeth ----------------- 0.03 0.23 
BPH Yes 1.07 <0.0001 No (Ref) (Ref) 	
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3. PSA as a continuous variable and number of teeth with severe bone loss: 
 The GEE model for PSA and number of teeth with severe bone loss controlling 
for potential confounders is presented in Table 10.3. 
 After controlling for age, BPH, BMI, education level, tobacco use, consuming 
more than 2 alcohol beverages a day, the use of NSAIDs, flossing frequency, and the 
number of teeth present, no statistically significant association was observed between 
PSA and number of teeth with severe bone loss (β= 0.16, p=0.24). 
 However, Age and BPH seem to be major confounders, as every year increase in 
age increases PSA by 0.06 ng/ml (β=0.06 p=0.02), and every switch from not having 
BPH to having BPH increases PSA by 1.05 ng/ml   (β=1.05 p=<0.0001). 
 There was no statistically significant association between PSA and BMI, 
education level, tobacco use, consuming more than 2 alcohol beverages a day, the use of 
NSAIDs, flossing frequency, and the number of teeth present. All the relationships were 
in a positive direction except for BMI and the use of tobacco: as for every unit increase in 
BMI and starting to use tobacco, PSA decreased by 0.08 and 0.18 ng/ml respectively 
Table10.3. 
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Table 10.3: Final GEE multivariate model to test the association between number of 
teeth with severe bone loss and PSA as a continuous variable, controlling for 
potential confounders (N=352). 	
Variable Levels Β estimate P-Value 
Intercept ----------------- -1.80 0.43 
No. of teeth with Severe bone loss ----------------- 0.16 0.24 
Age ----------------- 0.06 0.016 
BMI ----------------- -0.08 0.07 
Education 
College graduate 0.54 0.08 
Some college 0.75 0.07 
High school or less (Ref) (Ref) 
Use of any form of tobacco Yes -0.18 0.72 No (Ref) (Ref) 
Consumes more than 2 alcohol 
drinks/day 
Yes 0.23 0.46 
No (Ref) (Ref) 
Use of NSAID medications Yes 0.25 0.35 No (Ref) (Ref) 
Flossing frequency Never 0.27 0.51 Once / month or more (Ref) (Ref) 
No. of teeth ----------------- 0.04 0.10 
BPH Yes 1.05 <0.0001 No (Ref) (Ref) 	
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4. PSA as a continuous variable and BPH with clinical attachment loss levels: 
 The GEE model for PSA and BPH with clinical attachment loss controlling for 
potential confounders is presented in Table 10.4. 
 After controlling for age, BPH, BMI, education level, tobacco use, consuming 
more than 2 alcohol beverages a day, the use of NSAIDs, flossing frequency, and the 
number of teeth present, it was noted that for every change from having no BPH and 
CAL<2.7mm to having BPH and CAL≥2.7mm, PSA increases significantly by 1.46 
ng/ml (β=1.46 p=0.0002). And for every change from having no BPH and CAL<2.7 to 
having BPH and CAL<2.7, PSA increases significantly by 0.95 ng/ml (β=0.95 p=0.002). 
However, every change from having no BPH and CAL<2.7 to having no BPH and 
CAL≥2.7, PSA increases by 0.15 ng/ml (β=0.15 p=0.07) and this increase did not reach 
statistical significance. This suggests that the increase in PSA is more related to BPH 
than to clinical attachment loss. 
 However, Age seems to be a major confounder, as every year increase in age PSA 
increases by 0.06 ng/ml (β=0.06 p=0.005). 
 There was no statistically significant association between PSA and BMI, 
education level, tobacco use, consuming more than 2 alcohol beverages a day, the use of 
NSAIDs, flossing frequency, and the number of teeth present. All the relationships were 
in a positive direction except for BMI and the use of tobacco: as for every unit increase in 
BMI and starting to use tobacco, PSA decreased by 0.07 and 0.11 ng/ml respectively 
Table10.4. 
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Table 10.4: Final GEE multivariate model to test the association between BPH with 
CAL levels and PSA as a continuous variable, controlling for potential confounders 
(N=352). 	
Variable Levels Β estimate P-Value 
Intercept ----------------- -1.80 0.43 
BPH with CAL level 
High CAL Disease 1.46 0.0002 
High CAL No Disease 0.15 0.71 
Low CAL Disease 0.95 0.002 
Low CAL  No Disease (Ref) (Ref) 
Age ----------------- 0.06 0.005 
BMI ----------------- -0.07 0.11 
Education 
College graduate 0.09 0.65 
Some college 0.31 0.19 
High school or less (Ref) (Ref) 
Use of any form of tobacco Yes -0.11 0.59 No (Ref) (Ref) 
Consumes more than 2 alcohol 
drinks/day 
Yes 0.12 0.46 
No (Ref) (Ref) 
Use of NSAID medications Yes 0.19 0.14 No (Ref) (Ref) 
Flossing frequency Never 0.20 0.32 Once / month or more (Ref) (Ref) 
No. of teeth ----------------- 0.04 0.10 	
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5. PSA as a continuous variable and prostatitis with clinical attachment loss levels: 
 The GEE model for PSA and prostatitis with clinical attachment loss controlling 
for potential confounders is presented in Table 10.5. 
 After controlling for age, BPH, BMI, education level, tobacco use, consuming 
more than 2 alcohol beverages a day, the use of NSAIDs, flossing frequency, and the 
number of teeth present. It was noted that for every change from having no prostatitis and 
CAL<2.7 to having prostatitis and CAL≥2.7, PSA increases by 1.18 ng/ml (β=1.18 
p=0.26), for every change from having no prostatitis and CAL<2.7 to having prostatitis 
and CAL<2.7, PSA increases by 1.16 ng/ml (β=1.16 p=0.08), and for every change from 
having no prostatitis and CAL<2.7 to having no prostatitis and CAL≥2.7, PSA increases 
by 0.48 ng/ml (β=0.48 p=0.20). ALL these changes did not reach statistical significance. 
 However, Age seems to be a major confounder, as every year increase in age PSA 
increases by 0.07 ng/ml (β=0.07 p=0.005). 
 There was no statistically significant association between PSA and BMI, 
education level, tobacco use, consuming more than 2 alcohol beverages a day, the use of 
NSAIDs, flossing frequency, and the number of teeth present. All the relationships were 
in a positive direction except for BMI and the use of tobacco: as for every unit increase in 
BMI and starting to use tobacco, PSA decreased by 0.07 and 0.13 ng/ml respectively 
Table10.5. 
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Table 10.5: Final GEE multivariate model to test the association between prostatitis 
with CAL levels and PSA as a continuous variable, controlling for potential 
confounders (N=352). 	
Variable Levels Β estimate P-Value 
Intercept ----------------- -2.1 0.36 
Prostatitis with CAL level 
High CAL Disease 1.18 0.26 
High CAL No Disease 0.48 0.20 
Low CAL Disease 1.16 0.08 
Low CAL  No Disease (Ref) (Ref) 
Age ----------------- 0.07 0.0005 
BMI ----------------- -0.07 0.11 
Education 
College graduate 0.07 0.69 
Some college 0.30 0.23 
High school or less (Ref) (Ref) 
Use of any form of tobacco Yes -0.13 0.56 No (Ref) (Ref) 
Consumes more than 2 alcohol 
drinks/day 
Yes 0.12 0.45 
No (Ref) (Ref) 
Use of NSAID medications Yes 0.19 0.15 No (Ref) (Ref) 
Flossing frequency Never 0.22 0.27 Once / month or more (Ref) (Ref) 
No. of teeth ----------------- 0.04 0.10 	
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6. PSA as a continuous variable and prostate cancer with clinical attachment loss 
levels: 
 The GEE model for PSA and prostate cancer with clinical attachment loss 
controlling for potential confounders is presented in Table 10.6. 
 After controlling for age, BPH, BMI, education level, tobacco use, consuming 
more than 2 alcohol beverages a day, the use of NSAIDs, flossing frequency, and the 
number of teeth present. It was noted that for every change from having no prostate 
cancer and CAL<2.7 to having prostate cancer and CAL≥2.7, PSA increases by 0.67 
ng/ml (β=0.67 p=0.60), for every change from having no prostate cancer and CAL<2.7 to 
having prostate cancer and CAL<2.7, PSA increases by 0.31 ng/ml (β=0.31 p=0.83), and 
for every change from having no prostate cancer and CAL<2.7 to having no prostate 
cancer and CAL≥2.7, PSA increases by 0.51 ng/ml (β=0.51 p=0.09). ALL these changes 
did not reach statistical significance. 
 However, Age seems to be a major confounder, as every year increase in age PSA 
increases by 0.07 ng/ml (β=0.07 p=0.001). 
 There was no statistically significant association between PSA and BMI, 
education level, tobacco use, consuming more than 2 alcohol beverages a day, the use of 
NSAIDs, flossing frequency, and the number of teeth present. All the relationships were 
in a positive direction except for BMI and the use of tobacco: as for every unit increase in 
BMI and starting to use tobacco, PSA decreased by 0.07 and 0.16 ng/ml respectively 
Table10.6. 
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Table 10.6: Final GEE multivariate model to test the association between prostate 
cancer with CAL level and PSA as a continuous variable, controlling for potential 
confounders (N=352). 	
Variable Levels Β estimate P-Value 
Intercept ----------------- -2.12 0.37 
Prostate cancer with CAL level 
High CAL Disease 0.67 0.60 
High CAL No Disease 0.51 0.09 
Low CAL Disease 0.31 0.83 
Low CAL  No Disease (Ref) (Ref) 
Age ----------------- 0.07 0.001 
BMI ----------------- -0.07 0.09 
Education 
College graduate 0.08 0.67 
Some college 0.32 0.18 
High school or less (Ref) (Ref) 
Use of any form of tobacco Yes -0.16 0.45 No (Ref) (Ref) 
Consumes more than 2 alcohol 
drinks/day 
Yes 0.12 0.49 
No (Ref) (Ref) 
Use of NSAID medications Yes 0.19 0.13 No (Ref) (Ref) 
Flossing frequency Never 0.21 0.28 Once / month or more (Ref) (Ref) 
No. of teeth ----------------- 0.04 0.07 	
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PSA as a categorical variable: 
 In this section we will be presenting 3 models in which we tested for the 
relationship between PSA as a categorical variable (PSA≥4ng/ml vs. PSA<4ng/ml) as the 
outcome and average clinical attachment loss, average probing pocket depth, and number 
of teeth with severe bone loss as the main predictors, controlling for potential 
confounders that include: Age, BMI, BPH, level of education, use of tobacco, consuming 
more than 2 alcoholic beverages a day, the use of NSAIDs, flossing frequency and the 
number of teeth present. 
 
1. PSA as a categorical variable and average clinical attachment loss: 
 The GEE model for PSA and average clinical attachment loss controlling for 
potential confounders is presented in Table 11.1. 
 After controlling for age, BPH, BMI, education level, tobacco use, consuming 
more than 2 alcohol beverages a day, the use of NSAIDs, flossing frequency, and the 
number of teeth present. No statistically significant association was observed between 
PSA and average clinical attachment loss (OR= 0.87 95%CI 0.66-1.16). 
 However, Age and BPH seem to be major confounders, as every year increase in 
age increases the odds of having PSA≥4ng/ml significantly by 8% (OR= 1.08 95%CI 
1.03-1.13), and those with BPH have 4.39 the odds of having PSA≥4ng/ml compared to 
those who do not have BPH (OR= 4.39 95%CI 1.78-10.78). 
 Those who were college graduates and who had some college were more likely to 
have PSA≥4ng/ml compared to those with high school or less (OR= 3.22 95%CI 1.30-
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7.89 and OR= 2.75 95%CI 1.24-7.36) respectively. There was no statistically significant 
association between PSA levels and BMI, tobacco use, consuming more than 2 alcohol 
beverages a day, the use of NSAIDs, flossing frequency, and the number of teeth present 
Table11.1. 
 
Table 11.1: Final GEE multivariate model to test the association between average 
clinical attachment loss and PSA as a categorical variable, controlling for potential 
confounders (N=352). 	
Variable Levels OR 95% CI P-Value 
Average clinical attachment loss 
(mm) 
-------------------- 0.87 0.66 , 1.16 0.36 
Age -------------------- 1.08 1.03 , 1.13 0.0006 
BPH Yes 4.39 1.78 , 10.78 0.001 No (Ref) (Ref) (Ref) 
BMI -------------------- 0.96 0.89 , 1.04 0.31 
Education 
College 
graduate 3.22 
1.30 , 7.89 0.01 
Some college 2.75 1.24 , 7.36 0.02 
High school or 
less (Ref) (Ref) (Ref) 
Use of any form of tobacco Yes 1.17 0.43 , 3.17 0.76 No (Ref) (Ref) (Ref) 
Consumes more than 2 alcohol 
drinks/day 
Yes 1.73 0.92 , 3.28 0.08 
No (Ref) (Ref) (Ref) 
Use of NSAID medications Yes 1.10 0.62 , 1.95 0.73 No (Ref) (Ref) (Ref) 
Flossing frequency 
Never 1.06 0.63 , 1.78 0.83 
Once / month or 
more (Ref) (Ref) (Ref) 
No. of teeth ----------------- 1.02 0.96 , 1.07 0.56 
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2. PSA as a categorical variable and average probing pocket depth: 
 The GEE model for PSA and average probing pocket depth controlling for 
potential confounders is presented in Table 11.2. 
 After controlling for age, BPH, BMI, education level, tobacco use, consuming 
more than 2 alcohol beverages a day, the use of NSAIDs, flossing frequency, and the 
number of teeth present. No statistically significant association was observed between 
PSA and average probing pocket depth (OR= 1.21 95%CI 0.70-2.1). 
 However, Age and BPH seem to be major confounders, as every year increase in 
age increases the odds of having PSA≥4ng/ml significantly by 8% (OR= 1.08 95%CI 
1.03-1.13), and those with BPH have 4.21 the odds of having PSA≥4ng/ml compared to 
those who do not have BPH (OR= 4.21 95%CI 1.67-10.62). 
 Those who were college graduates and who had some college were more likely to 
have PSA≥4ng/ml compared to those with high school or less (OR= 3.18 95%CI 1.27-
7.94 and OR= 3.0 95%CI 1.23-7.28) respectively. There was no statistically significant 
association between PSA levels and BMI, tobacco use, consuming more than 2 alcohol 
beverages a day, the use of NSAIDs, flossing frequency, and the number of teeth present 
Table11.2. 
 
 
 
 
		 94	
Table 11.2: Final GEE multivariate model to test the association between average 
probing pocket depth and PSA as a categorical variable, controlling for potential 
confounders (N=352). 	
Variable Levels OR 95% CI P-Value 
Average probing pocket depth 
(mm) 
-------------------- 1.21 0.7 , 2.1 0.49 
Age -------------------- 1.08 1.03 , 1.13 0.001 
BPH Yes 4.21 1.67 , 10.62 0.002 No (Ref) (Ref) (Ref) 
BMI -------------------- 0.95 0.88 , 1.04 0.27 
Education 
College 
graduate 3.18 
1,27 , 7.94 0.01 
Some college 3.0 1.23 , 7.28 0.02 
High school or 
less (Ref) (Ref) (Ref) 
Use of any form of tobacco Yes 1.08 0.39 , 3.10 0.88 No (Ref) (Ref) (Ref) 
Consumes more than 2 alcohol 
drinks/day 
Yes 1.78 0.95 , 3.34 0.07 
No (Ref) (Ref) (Ref) 
Use of NSAID medications Yes 1.11 0.63 , 2.0 0.7 No (Ref) (Ref) (Ref) 
Flossing frequency 
Never 1.04 0.62 , 1.77 0.9 
Once / month or 
more (Ref) (Ref) (Ref) 
No. of teeth ----------------- 1.03 1.0 , 1.08 0.15 	
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3. PSA as a categorical variable and number of teeth with severe bone loss: 
 The GEE model for PSA and number of teeth with severe bone loss controlling 
for potential confounders is presented in Table 11.3. 
 After controlling for age, BPH, BMI, education level, tobacco use, consuming 
more than 2 alcohol beverages a day, the use of NSAIDs, flossing frequency, and the 
number of teeth present. No statistically significant association was observed between 
PSA and the number of teeth with Severe bone loss (OR= 1.01 95%CI 0.86-1.18). 
 However, Age and BPH seem to be major confounders, as every year increase in 
age increases the odds of having PSA≥4ng/ml significantly by 10% (OR= 1.10 95%CI 
1.04-1.15), and those with BPH have 4.21 the odds of having PSA≥4ng/ml compared to 
those who do not have BPH (OR= 4.21 95%CI 1.61-10.98). 
 Those who were college graduates and who had some college were more likely to 
have PSA≥4ng/ml compared to those with high school or less (OR= 2.95 95%CI 1.18-
7.33 and OR= 3.06 95%CI 1.24-7.57) respectively, consuming more than 2 alcohol 
beverages a day and the number of teeth present were statistically associated with PSA 
levels (OR= 1.99 95%CI 1.06-3.73 and OR= 1.06 95%CI 1.003-1.12) respectively. There 
was no statistically significant association between PSA levels and BMI, tobacco use, the 
use of NSAIDs, and flossing frequency Table11.3. 
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Table 11.3: Final GEE multivariate model to test the association number of teeth 
with severe bone loss and PSA as a categorical variable, controlling for potential 
confounders (N=352). 	
Variable Levels OR 95% CI P-Value 
No. of teeth with Severe bone loss -------------------- 1.01 0.86 , 1.18 0.92 
Age -------------------- 1.10 1.04 , 1.15 0.001 
BPH Yes 4.21 1.61 , 10.98 0.003 No (Ref) (Ref) (Ref) 
BMI -------------------- 0.97 0.89 , 1.06 0.47 
Education 
College 
graduate 2.95 
1.18 , 7.33 0.02 
Some college 3.06 1.24 , 7.57 0.02 
High school or 
less (Ref) (Ref) (Ref) 
Use of any form of tobacco Yes 1.20 0.41 , 3.53 0.74 No (Ref) (Ref) (Ref) 
Consumes more than 2 alcohol 
drinks/day 
Yes 1.99 1.06 , 3.73 0.03 
No (Ref) (Ref) (Ref) 
Use of NSAID medications Yes 0.97 0.53 , 1.76 0.92 No (Ref) (Ref) (Ref) 
Flossing frequency 
Never 0.93 0.52 , 1.66 0.81 
Once / month or 
more (Ref) (Ref) (Ref) 
No. of teeth ----------------- 1.06 1.003, 1.12 0.04 	
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Benign prostate hyperplasia (BPH): 
 In this section we will be presenting 3 models in which we tested for the 
relationship between BPH as the outcome variable and average clinical attachment loss, 
average probing pocket depth, and number of teeth with severe bone loss, controlling for 
potential confounders that include: Age, PSA, BMI, level of education, use of tobacco, 
consuming more than 2 alcoholic beverages a day, the use of NSAIDs, flossing frequency 
and the number of teeth present. 
 
1. BPH and average clinical attachment loss: 
 The GEE model for BPH and average clinical attachment loss controlling for 
potential confounders is presented in Table 12.1. 
 After controlling for age, PSA, BMI, education level, tobacco use, consuming 
more than 2 alcohol beverages a day, the use of NSAIDs, flossing frequency, and the 
number of teeth present, we found that for every millimeter increase in average clinical 
attachment loss the odds of having BPH increase by 41% (OR= 1.41 95%CI 1.02-1.96) 
Age and PSA seem to be major confounders, as every year increase in age 
increases the odds of having BPH by 12% (OR= 1.12 95%CI 1.06-1.17), and every 
switch from having PSA <4ng/ml to having PSA≥4ng/ml increases the odds of having 
BPH by 75% (OR= 1.75 95%CI 1.06-2.88) 
 There was no statistically significant association between BPH and BMI, 
education level, tobacco use, consuming more than 2 alcohol beverages a day, the use of 
NSAIDs, flossing frequency, and the number of teeth present Table12.1. 
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Table 12.1: Final GEE multivariate model to test the association between average 
clinical attachment loss and BPH, controlling for potential confounders (N=352). 
 
Variable Levels OR 95% CI P-Value 
Average clinical attachment loss 
(mm) 
-------------------- 1.41 1.02 , 1.96 0.04 
PSA cat. ≥ 4ng/ml 1.75 1.06 , 2.88 0.03 <4ng/ml (Ref) (Ref) (Ref) 
Age -------------------- 1.12 1.06 , 1.17 <0.0001 
BMI -------------------- 1.0 0.93 , 1.08 0.96 
Education 
College 
graduate 1.0 
0.47 ,  2.11 0.99 
Some college 1.25 0.60 , 2.64 0.55 
High school or 
less (Ref) (Ref) (Ref) 
Use of any form of tobacco Yes 0.68 0.39 , 1.19 0.18 No (Ref) (Ref) (Ref) 
Consumes more than 2 alcohol 
drinks/day 
Yes 1.33 0.98 , 1.81 0.07 
No (Ref) (Ref) (Ref) 
Use of NSAID medications Yes 1.01 0.56 , 1.83 0.96 No (Ref) (Ref) (Ref) 
Flossing frequency 
Never 1.0 0.71 , 1.40 0.99 
Once / month or 
more (Ref) (Ref) (Ref) 
No. of teeth ----------------- 1.05 1.0 , 1.12 0.06 
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2. BPH and average probing pocket depth: 
 The GEE model for BPH and average probing pocket depth controlling for 
potential confounders is presented in Table 12.2. 
 After controlling for age, PSA, BMI, education level, tobacco use, consuming 
more than 2 alcohol beverages a day, the use of NSAIDs, flossing frequency, and the 
number of teeth present, no statistically significant association was observed between 
BPH and average probing pocket depth (OR= 1.01 95%CI 0.61-1.66) 
However, Age seems to be a major confounder, as every year increase in age 
increases the odds of having BPH by 13% (OR= 1.13 95%CI 1.07-1.18). While every 
switch from having PSA <4ng/ml to having PSA≥4ng/ml increases the odds of having 
BPH by 59% (OR= 1.59 95%CI 0.98-2.59) this relation was not statistically significant. 
 There was no statistically significant association between BPH and BMI, 
education level, tobacco use, consuming more than 2 alcohol beverages a day, the use of 
NSAIDs, flossing frequency, and the number of teeth present Table12.2. 
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Table 12.2: Final GEE multivariate model to test the association between average 
probing pocket depth and BPH, controlling for potential confounders (N=352). 	
Variable Levels OR 95% CI P-Value 
Average probing pocket depth 
(mm) 
-------------------- 1.01 0.61 , 1.66 0.97 
PSA cat. ≥ 4ng/ml 1.59 0.98 , 2.59 0.06 <4ng/ml (Ref) (Ref) (Ref) 
Age -------------------- 1.13 1.07 , 1.18 <0.0001 
BMI -------------------- 1.004 0.93 , 1.08 0.92 
Education 
College 
graduate 0.92 
0.43 , 2.0 0.84 
Some college 1.30 0.61 , 2.74 0.50 
High school or 
less (Ref) (Ref) (Ref) 
Use of any form of tobacco Yes 0.78 0.46 , 1.34 0.37 No (Ref) (Ref) (Ref) 
Consumes more than 2 alcohol 
drinks/day 
Yes 1.28 0.98 , 1.68 0.07 
No (Ref) (Ref) (Ref) 
Use of NSAID medications Yes 1.02 0.55 , 1.87 0.96 No (Ref) (Ref) (Ref) 
Flossing frequency 
Never 0.98 0.72 , 1.34 0.91 
Once / month or 
more (Ref) (Ref) (Ref) 
No. of teeth ----------------- 1.02 0.97 , 1.07 0.37 	
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3. BPH and the number of teeth with severe bone loss: 
 The GEE model for BPH and the number of teeth with severe bone loss 
controlling for potential confounders is presented in Table 12.3. 
 After controlling for age, PSA, BMI, education level, tobacco use, consuming 
more than 2 alcohol beverages a day, the use of NSAIDs, flossing frequency, and the 
number of teeth present, no statistically significant association was observed between 
BPH and the number of teeth with severe bone loss (OR= 1.02 95%CI 0.86-1.20) 
However, Age seems to be a major confounder, as every year increase in age 
increases the odds of having BPH by 13% (OR= 1.13 95%CI 1.06-1.19). While every 
switch from having PSA <4ng/ml to having PSA≥4ng/ml increases the odds of having 
BPH by 54% (OR= 1.54 95%CI 0.89-2.66) this relation was not statistically significant. 
 There was no statistically significant association between BPH and BMI, 
education level, tobacco use, consuming more than 2 alcohol beverages a day, the use of 
NSAIDs, flossing frequency, and the number of teeth present Table12.3. 
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Table 12.3: Final GEE multivariate model to test the association between number of 
teeth with severe bone loss and BPH, controlling for potential confounders (N=352).  	
Variable Levels OR 95% CI P-Value 
No. of teeth with Severe bone loss -------------------- 1.02 0.86 , 1.20 0.84 
PSA cat. ≥ 4ng/ml 1.54 0.89 , 2.66 0.13 <4ng/ml (Ref) (Ref) (Ref) 
Age -------------------- 1.13 1.06 , 1.19 <0.0001 
BMI -------------------- 1.01 0.94 , 1.09 0.72 
Education 
College 
graduate 0.93 
0.40 , 2.18 0.87 
Some college 1.26 0.55 , 2.90 0.59 
High school or 
less (Ref) (Ref) (Ref) 
Use of any form of tobacco Yes 0.77 0.42 , 1.41 0.39 No (Ref) (Ref) (Ref) 
Consumes more than 2 alcohol 
drinks/day 
Yes 1.08 0.81 , 1.45 0.61 
No (Ref) (Ref) (Ref) 
Use of NSAID medications Yes 1.07 0.52 , 2.22 0.85 No (Ref) (Ref) (Ref) 
Flossing frequency 
Never 1.0 0.69 , 1.40 0.91 
Once / month or 
more (Ref) (Ref) (Ref) 
No. of teeth ----------------- 1.01 0.96 , 1.07 0.67 
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Prostatitis: 
 In this section we will be presenting 2 models in which we tested for the 
relationship between Prostatitis as the outcome variable and average clinical attachment 
loss and average probing pocket depth, controlling for potential confounders that include: 
Age, PSA, BMI, level of education, use of tobacco, the use of NSAIDs, flossing 
frequency and the number of teeth present. It should be noted that no model for the 
relationship between Prostatitis the number of teeth with severe bone loss is presented, 
this due to our inability to generate any model, as a small proportion of the study sample 
have prostatitis as well as the low number of teeth with severe bone loss. 
 
1. Prostatitis and average clinical attachment loss: 
 The GEE model for Prostatitis and average clinical attachment loss controlling for 
potential confounders is presented in Table 13.1. 
After controlling for age, PSA, BMI, education level, tobacco use, the use of 
NSAIDs, flossing frequency, and the number of teeth present, no statistically significant 
association was observed between Prostatitis and average clinical attachment loss (OR= 
0.94  95%CI 0.76-1.16) 
It is worth noting that age did not show a statistically significant association with 
prostatitis.  
 There was no statistically significant association between prostatitis and PSA, 
BMI, education level, tobacco use, the use of NSAIDs, flossing frequency, and the 
number of teeth present Table13.1. 
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Table 13.1: Final GEE multivariate model to test the association between average 
clinical attachment loss and prostatitis, controlling for potential confounders 
(N=352). 
  
Variable Levels OR 95% CI P-Value 
Average clinical attachment loss 
(mm) 
-------------------- 0.94 0.76 , 1.16 0.57 
PSA cat. ≥ 4ng/ml 1.04 0.93 , 1.17 0.49 <4ng/ml (Ref) (Ref) (Ref) 
Age -------------------- 1.02 0.99 , 1.10 0.20 
BMI -------------------- 0.98 0.95 , 1.03 0.45 
Education 
College 
graduate 1.86 
0.62 , 5.63 0.27 
Some college 1.68 0.50 , 5.31 0.38 
High school or 
less (Ref) (Ref) (Ref) 
Use of any form of tobacco Yes 0.90 0.75 , 1.08 0.27 No (Ref) (Ref) (Ref) 
Use of NSAID medications Yes 1.03 0.95 , 1.12 0.51 No (Ref) (Ref) (Ref) 
Flossing frequency 
Never 0.93 0.83 , 1,05 0.26 
Once / month or 
more (Ref) (Ref) (Ref) 
No. of teeth ----------------- 1.01 0.99 , 1.04 0.31 														
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2. Prostatitis and average probing pocket depth: 
 The GEE model for Prostatitis and average probing pocket depth controlling for 
potential confounders is presented in Table 13.2. 
After controlling for age, PSA, BMI, education level, tobacco use, the use of 
NSAIDs, flossing frequency, and the number of teeth present, no statistically significant 
association was observed between Prostatitis and average probing pocket depth (OR= 
0.98  95%CI 0.86-1.12) 
It is worth noting that age did not show a statistically significant association with 
prostatitis.  
 There was no statistically significant association between prostatitis and PSA, 
BMI, education level, tobacco use, the use of NSAIDs, flossing frequency, and the 
number of teeth present Table13.2. 
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Table 13.2: Final GEE multivariate model to test the association between average 
probing pocket depth and prostatitis, controlling for potential confounders  
(N=352). 	
Variable Levels OR 95% CI P-Value 
Average probing pocket depth 
(mm) 
-------------------- 0.98 0.86 , 1.12 0.75 
PSA cat. ≥ 4ng/ml 1.01 0.93 , 1.11 0.74 <4ng/ml (Ref) (Ref) (Ref) 
Age -------------------- 1.02 1.0 , 1.05 0.21 
BMI -------------------- 1.0 0.97 , 1.03 0.89 
Education 
College 
graduate 1.88 
0.60 , 5.90 0.28 
Some college 1.82 0.59 , 5.61 0.30 
High school or 
less (Ref) (Ref) (Ref) 
Use of any form of tobacco Yes 0.93 0.85 , 1.01 0.08 No (Ref) (Ref) (Ref) 
Use of NSAID medications Yes 1.02 0.97 , 1.08 0.48 No (Ref) (Ref) (Ref) 
Flossing frequency 
Never 0.94 0.87 , 1.01 0.07 
Once / month or 
more (Ref) (Ref) (Ref) 
No. of teeth ----------------- 1.01 1.0 , 1.03 0.11 																	
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Prostate Cancer: 
 In this section we will be presenting 3 models in which we tested for the 
relationship between prostate cancer as the outcome variable and average clinical 
attachment loss, average probing pocket depth, and number of teeth with severe bone 
loss, controlling for potential confounders that include: Age, PSA, BMI, level of 
education, use of tobacco, the use of NSAIDs, flossing frequency and the number of teeth 
present. 
 
1. Prostate cancer and average clinical attachment loss: 
 The GEE model for prostate cancer and average clinical attachment loss 
controlling for potential confounders is presented in Table 14.1. 
After controlling for age, PSA, BMI, education level, tobacco use, the use of 
NSAIDs, flossing frequency, and the number of teeth present, no statistically significant 
association was observed between Prostate cancer and average clinical attachment loss 
(OR= 0.88  95%CI 0.68-1.13). 
However, Age seems to be a major confounder, as every year increase in age 
increases the odds of having Prostate cancer by 11% (OR= 1.11 95%CI 1.06-1.18). 
There was no statistically significant association between Prostate cancer and 
PSA, BMI, education level, tobacco use, the use of NSAIDs, flossing frequency, and the 
number of teeth present Table14.1. 
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Table 14.1: Final GEE multivariate model to test the association between average 
clinical attachment loss and prostate cancer, controlling for potential confounders 
(N=352). 	
Variable Levels OR 95% CI P-Value 
Average clinical attachment loss 
(mm) 
-------------------- 0.88 0.68 , 1.13 0.30 
PSA cat. ≥ 4ng/ml 0.64 0.22 , 1.87 0.41 <4ng/ml (Ref) (Ref) (Ref) 
Age -------------------- 1.11 1.06 , 1.18 <0.0001 
BMI -------------------- 1.04 0.95 , 1.12 0.41 
Education 
College 
graduate 1.54 
0.53 , 4.43 0.43 
Some college 1.32 0.48 , 3.64 0.59 
High school or 
less (Ref) (Ref) (Ref) 
Use of any form of tobacco Yes 0.51 0.19 , 1.36 0.18 No (Ref) (Ref) (Ref) 
Use of NSAID medications Yes 0.82 0.50 , 1.33 0.42 No (Ref) (Ref) (Ref) 
Flossing frequency 
Never 0.76 0.41 , 1.41 0.38 
Once / month or 
more (Ref) (Ref) (Ref) 
No. of teeth ----------------- 0.99 0.94 , 1.03 0.57 																	
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2. Prostate cancer and average probing pocket depth: 
 The GEE model for Prostate cancer and average probing pocket depth controlling 
for potential confounders is presented in Table 14.2. 
After controlling for age, PSA, BMI, education level, tobacco use, the use of 
NSAIDs, flossing frequency, and the number of teeth present, n statistically significant 
association was observed between Prostate cancer and average probing pocket depth 
(OR= 1.0  95%CI 0.63-1.53). 
However, Age seems to be a major confounder, as every year increase in age 
increases the odds of having Prostate cancer by 11% (OR= 1.11 95%CI 1.05-1.17). 
There was no statistically significant association between Prostate cancer and 
PSA, BMI, education level, tobacco use, the use of NSAIDs, flossing frequency, and the 
number of teeth present Table14.2. 
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Table 14.2: Final GEE multivariate model to test the association between average 
probing pocket depth and prostate cancer, controlling for potential confounders 
(N=352). 	
Variable Levels OR 95% CI P-Value 
Average probing pocket depth 
(mm) 
-------------------- 1.0 0.63 , 1.53 0.95 
PSA cat. ≥ 4ng/ml 0.64 0.21 , 1.93 0.43 <4ng/ml (Ref) (Ref) (Ref) 
Age -------------------- 1.11 1.05 , 1.17 0.0004 
BMI -------------------- 1.04 0.96 , 1.13 0.35 
Education 
College 
graduate 1.53 
0.93 , 4.50 0.44 
Some college 1.33 0.47 , 3.73 0.59 
High school or 
less (Ref) (Ref) (Ref) 
Use of any form of tobacco Yes 0.53 0.21 , 1.34 0.18 No (Ref) (Ref) (Ref) 
Use of NSAID medications Yes 0.81 0.49 , 1.32 0.39 No (Ref) (Ref) (Ref) 
Flossing frequency 
Never 0.74 0.39 , 1.40 0.36 
Once / month or 
more (Ref) (Ref) (Ref) 
No. of teeth ----------------- 1.0 0.95 , 1.05 0.98 																	
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3. Prostate cancer and the number of teeth with severe bone loss: 
 The GEE model for BPH and the number of teeth with severe bone loss 
controlling for potential confounders is presented in Table 14.3. 
After controlling for age, PSA, tobacco use, flossing frequency, and the number 
of teeth present, no statistically significant association was observed between Prostate 
cancer and the number of teeth with severe bone loss (OR= 0.93  95%CI 0.80-1.08). 
However, Age seems to be a major confounder, as every year increase in age 
increases the odds of having Prostate cancer by 7% (OR= 1.07 95%CI 1.03-1.11). 
There was no statistically significant association between Prostate cancer and 
PSA, tobacco use, flossing frequency, and the number of teeth present Table14.3. 
 
Table 14.3: Final GEE multivariate model to test the association between number of 
teeth with severe bone loss and prostate cancer, controlling for potential 
confounders (N=352). 
Variable Levels OR 95% CI P-Value 
No. of teeth with Severe bone loss -------------------- 0.93 0.80 , 1.08 0.35 
PSA cat. ≥ 4ng/ml 0.60 0.21 , 1.70 0.33 <4ng/ml (Ref) (Ref) (Ref) 
Age -------------------- 1.07 1.03 , 1.11 0.001 
Use of any form of tobacco Yes 0.50 0.25 , 0.95 0.04 No (Ref) (Ref) (Ref) 
Flossing frequency 
Never 0.60 0.32 , 1.13 0.11 
Once / month or 
more (Ref) (Ref) (Ref) 
No. of teeth ----------------- 1.0 0.95 , 1.05 0.87 
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Table 15.1:  Summary table for final GEE multivariate models of PSA as a 
continuous variable (N=352). 
Variable Levels B P-Value 
Average clinical attachment loss 
(mm) 
----------------- -0.005 0.97 
    
Average probing pocket depth (mm) -------------------- 0.25 0.41 
    
No. of teeth with Severe bone loss -------------------- 0.16 0.24 
    
BPH with CAL level 
High CAL Disease 1.46 0.0002 
High CAL No Disease 0.15 0.71 
Low CAL Disease 0.95 0.002 
Low CAL  No Disease (Ref) (Ref) 
    
Prostatitis with CAL level 
High CAL Disease 1.18 0.26 
High CAL No Disease 0.48 0.20 
Low CAL Disease 1.16 0.08 
Low CAL  No Disease (Ref) (Ref) 
    
Prostate cancer with CAL level 
High CAL Disease 0.67 0.60 
High CAL No Disease 0.51 0.09 
Low CAL Disease 0.31 0.83 
Low CAL  No Disease (Ref) (Ref) 
 
 
Table 15.2: Summary table for all final GEE multivariate models (N=352). 
Variable 
PSA 
OR 
(95% CI) 
 BPH 
OR 
(95% CI) 
 Prostatitis 
OR 
(95% CI) 
 PrCa 
OR 
(95% CI) 
Average clinical 
attachment loss (mm) 
0.87 
(0.66,1.13) 
 1.41 
(1.02,1.96) 
 0.94 
(0.76,1.17) 
 0.88 
(0.68,1.13) 
        
Average probing pocket 
depth (mm) 
1.21 
(0.7,2.1) 
 1.01 
(0.61,1.66) 
 0.98 
(0.86,1.12) 
 1.0 
(0.63,1.53) 
        
No. of teeth with Severe 
bone loss 
1.01 
(0.86,1.18) 
 1.02 
(0.86,1.20) 
 ______  0.93 
(0.80,1.08) 
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DISCUSSION: 
  The overall objective of this study was to evaluate the relationship between 
different diseases of the prostate gland (Benign Prostate Hyperplasia, Prostatitis, and 
Prostate Cancer) as well as levels of Prostate specific Antigen (PSA) with periodontal 
disease. To the best of our knowledge, no previous studies have evaluated this potential 
relationship on longitudinal data.  
In our study, we found that after controlling for potential confounders (age, PSA, 
BMI, education level, tobacco use, consuming more than 2 alcohol beverages a day, the 
use of NSAIDs, flossing frequency, and the number of teeth present) there was a 
statistically significant association between average clinical attachment loss and BPH, as 
for every millimeter increase in average clinical attachment loss the odds of having BPH 
increase by 41%. This comes in agreement with a study done by Boland et al. who found 
an association between BPH and periodontal disease using linked electronic medical and 
dental records. Although their sample size was large, it should be noted that 
methodological flaws did exist due to the cross-sectional design and the use of electronic 
diagnoses and billing codes. For instance, the control subjects could have some disease 
that were not coded, or they could have received treatment elsewhere. There is also the 
issue of the inability to distinguish between the severities of the diseases. Their analysis 
was limited to subjects under the age of 70 years (Boland et al., 2013), where in our study 
the mean age was 71 years which gave us a better chance to study both diseases. Both 
BPH and periodontal disease are associated with an increase in age, which is clear in our 
sample as well as in the literature (Berry et al., 1984; American Academy of 
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periodontology (c), 2005; Albandar, 2002). When using Average probing pocket depth 
and the number of teeth with severe bone loss as the measures for periodontal disease, no 
statistically significant association was observed between BPH and those measures.  
We have also found an association that has not been previously reported in the 
literature. We found that after controlling for potential confounders, those with BPH and 
average clinical attachment loss whether more or less than 2.7 mm, had statistically 
significant higher PSA levels compared to subjects without BPH and either average 
clinical attachment loss above or below 2.7 mm. Among those with BPH, subjects with 
average clinical attachment loss more than 2.7mm had higher PSA levels than subjects 
with average clinical attachment loss less than 2.7mm, however this difference was not 
statistically significant. This might suggest that the elevation in PSA is more due to 
having BPH, as BPH has been linked to increase levels of PSA (Stamey et al., 1987; 
Sarma and Wei, 2012). 
Our findings are consistent with the literature as we observed a relationship 
between age and the different diseases of the prostate gland (Benign Prostate 
Hyperplasia, Prostatitis, and Prostate Cancer) (Berry et al., 1984; Sarma and Wei, 2012; 
Calhoun et al., 2004; Jemal et al., 2007), as well as a relationship between elevated PSA 
levels and the different diseases of the prostate gland (Benign Prostate Hyperplasia, 
Prostatitis, and Prostate Cancer) (Stamey et al., 1987; Sarma and Wei, 2012). However, 
we did not find an association between PSA and any of the periodontal disease 
parameters (average clinical attachment loss, average probing pocket depth, and number 
of teeth with severe bone loss). In support to the findings of this study, Joshi et al. found 
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no association between prostatitis and any of the periodontal disease measurements used 
in their study (Joshi et al., 2010). 
No association was found between prostate cancer and any of the periodontal 
disease parameters (average clinical attachment loss, average probing pocket depth, and 
number of teeth with severe bone loss). After controlling for potential confounders, no 
statistically significant difference was found in the level of PSA among those with 
prostate cancer and average clinical attachment loss more than 2.7 mm compared to 
subjects having either of the conditions.  
Moreover, no association between prostatitis and any of the periodontal disease 
parameters (average clinical attachment loss, and average probing pocket depth) was 
detected. This comes in agreement with the results shown by Joshi et al. Further 
controlling for potential confounders failed to show any statistically significant difference 
in the level of PSA among those with prostatitis and average clinical attachment loss 
more than 2.7 mm compared to subjects having either of the conditions. This contradicts 
the results of the previous work conducted by Joshi et al.  
It should be noted that in our crude analysis, before controlling for potential 
confounders, those with prostatitis and average clinical attachment loss (whether more or 
less than 2.7mm) had statistically significant higher PSA levels compared to subjects 
without prostatitis and either average clinical attachment loss above or below 2.7mm, 
which comes in agreement with the results obtained by Joshi et al. This later finding 
highlights the importance of controlling for potential confounders, as the study by Joshi 
et al. had several limitations, mainly the small sample size, the low age group, and the 
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cross sectional nature of the study. There was no control group and there was no 
controlling for potential confounders. There was no recording of changes of PSA levels 
over time and the division of severity of prostatitis was based on a needle biopsy that may 
not show the whole state of the gland (Joshi et al., 2010).  
The potential mechanisms to explain the results found by both Boland et al. and 
Joshi et al. seem to apply to our study as well. A good explanation of the association 
between periodontal disease and BPH comes from the mutual role that inflammation 
plays in both diseases (Amar et al. 2003, Nickel 2008), as both diseases have been 
associated with an increase in pro-inflammatory cytokines and tissue destructive 
mediators like IL-1, IL-2, TNF-α, C-reactive protein (CRP), as well as transforming 
growth factor beta (TGF-β), an important growth factor involved in the immune response 
and wound healing (Offenbacher , 1996; Loos et al., 2000; Birkedal, 1993; Noack et al., 
2001; Skaleric et al. 1997, Untergasser et al. 2005; St Sauver et al., 2006; St Sauver et al., 
2008; St Sauver et al., 2009). Another explanation could be the mutual association that 
both BPH and periodontal disease have with ED, hence possibly linking them together 
(Zadik et al. 2009, Keller et al. 2012; Mcvary 2005, Costabile and Steers, 2006). To 
explain the increase in PSA levels among those with BPH and average clinical 
attachment loss above 2.7mm, the proposed mechanisms by Joshi et al. seem to apply. 
These mechanisms are based on the role that pro-inflammatory cytokines like IL1 and 
TNF-α play in both diseases (Offenbacher , 1996; Loos et al., 2000; Birkedal, 1993; 
Noack et al., 2001; Skaleric et al. 1997, Untergasser et al. 2005; St Sauver et al., 2006; St 
Sauver et al., 2008; St Sauver et al., 2009). The first possible mechanism could be that 
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periodontitis could indirectly exaggerate pre-existing inflammation of the prostate gland 
through circulating cytokines. The second proposed mechanism is that the inflammatory 
response causes a disruption in the epithelium of the prostate gland leading to PSA 
leakage into the circulation. The third possibility is that the inflammatory response 
associated with prostate gland enlargements leads to an increase in the production of PSA 
both locally from the gland itself as well as a non-prostatic source of PSA like the 
periodontium. 
 
Implications: 
 
 Our findings add to the body of the literature, as to the best of our knowledge no 
previous studies have evaluated the potential relationship between different diseases of 
the prostate gland (Benign Prostate Hyperplasia, Prostatitis, and Prostate Cancer) as well 
as levels of Prostate specific Antigen (PSA) with periodontal disease on longitudinal 
data. 
The findings of this study could potentially help add periodontal therapy and 
maintenance, as part of the overall management of patients with prostate disease and 
elevated PSA levels. The relationship found between BPH and periodontal disease, 
supports that periodontal disease may play a role in other systemic diseases and 
emphasizes the importance of oral health as an integral and important part of general 
health and well-being.  
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Strengths and Limitations: 
 
 The main strength of our study comes from its longitudinal prospective cohort 
study design, as to the best of our knowledge no previous studies have evaluated the 
potential relationship between different diseases of the prostate gland (Benign Prostate 
Hyperplasia, Prostatitis, and Prostate Cancer) as well as levels of Prostate specific 
Antigen (PSA) with periodontal disease on longitudinal data. The data set gave us a lot of 
variables to look at as well as a large sample size; this allowed us to better control for 
potential confounders, as well as the ability to use advanced statistical analysis to account 
for the	collinearity and repeated measure in the data.  
 It should be noted that despite the strong study design, there are several 
limitations. We were unable to control for the confounding effect of race and ethnicity in 
our study, as the majority of the DLS sample are Caucasian males. Another limitation 
was having many missing variables, where we tried to control for that using advanced 
statistical methods. The different diseases of the prostate gland (Benign Prostate 
Hyperplasia, Prostatitis, and Prostate Cancer) were recorded once as present or absent, 
there was no recording of changes in disease status, as well as no recording of any 
treatment provided to the patient. It should be noted that there was a small proportion of 
our sample who were diagnosed with prostatitis (7.4%) and prostate cancer (8.8%), 
compared to those diagnosed with BPH (79.6%). This small proportion of both diseases 
may explain the inability of finding any statistically significant relationship with any of 
the periodontal disease parameters, as well as the inability to perform statistical testing 
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for some variables. Another limitation, which is also a limitation of many studies that 
involve periodontal disease, is the lack of a clear case definition for periodontal disease 
and the different cut off points used in these studies. In this study we used 2.7mm as a cut 
off for average clinical attachment loss, we have adapted this cut off from Joshi et al. in 
an attempt to try to mimic their study, this cutoff was close to the median average clinical 
attachment loss in our study (2.63mm), however when we used other cutoff points no 
statistically significant differences were observed. Using different cut offs for periodontal 
disease as well as other parameters have the potential to yield different results.  
 
Future Study Directions: 
 
The results of our study add to the body of the literature, specifically in the 
relationship between different diseases of the prostate gland (Benign Prostate 
Hyperplasia, Prostatitis, and Prostate Cancer) as well as levels of Prostate specific 
Antigen (PSA) with periodontal disease, and generally in the relationship between 
periodontal disease and systemic diseases. Future studies should also be longitudinal, 
with emphasis on changes in disease status and the treatment provided. Having a 
population that is diverse in race and ethnicity is important for controlling for it’s 
confounding effect. If another longitudinal study can show the same findings, this will 
support the importance of adding periodontal therapy and maintenance, as part of the 
overall management of patients with prostate disease and elevated PSA levels. This will 
also support that periodontal disease may play a role in other systemic diseases and 
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emphasizes the importance of oral health as an integral and important part of general 
health and well-being.  
 	
Summary and Conclusion: 
 In conclusion, the results of our study show a relationship between an increase in 
average clinical attachment loss and BPH. Additionally, the results show that those with 
BPH and average clinical attachment loss above 2.7mm have higher PSA levels than 
those with either condition alone. These findings support that periodontal disease could 
affect the health of the prostate gland in an aging population, as well as the importance of 
oral health as an important and integral part of general health and well-being.  
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